Citations & References

“The regenerative medicine revolution is upon us. Like iron and steel to the industrial revolution, like the microchip to the tech revolution, stem cells will be the driving force of this next revolution.”
Cade Hildreth, founder of BioInformant, a stem cell industry research firm. Citado por: Tony Robbins,
Peter Diamandis and Robert Hariri. Life Force; Simon and Schuster, 2022.

“Stem cells seem to hold major promise for contemporary medicine, one which could almost be more significant than a discovery of DNA”
Kurpisz M. New Technologies Based on Stem Cell-Therapies in Regenerative Medicine and Reproductive
Biology. Cells. 2022 Dec 26;12(1):95.

OSTEOARTHRITIS

DISEASES AND PAIN

Lim HC, Park YB, Ha CW, Cole BJ, Lee BK, Jeong HJ, et al. Allogeneic
Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation
Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older
Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year
Clinical Follow-up. Orthop J Sports Med. 2021;9(1):2325967120973052.
doi: 10.1177/2325967120973052.
Issa MR, Naja AS, Bouji NZ, Sagherian BH. The role of adipose-derived
mesenchymal stem cells in knee osteoarthritis: a meta-analysis of
randomized controlled trials. Ther Adv Musculoskelet Dis.
2022;14:1759720X221146005. doi: 10.1177/1759720X221146005.
Zhang Y, Yang H, He F, Zhu X. Intra-articular injection choice for
osteoarthritis: making sense of cell source-an updated systematic review
and dual network meta-analysis. Arthritis Res Ther. 2022;24(1):260. doi:
10.1186/s13075-022-02953-0.
Zhao J, Liang G, Han Y, Yang W, Xu N, Luo M, et al. Combination of
mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in the
treatment of knee osteoarthritis: a meta-analysis of randomised
controlled trials. BMJ Open. 2022;12(11):e061008. doi:
10.1136/bmjopen-2022-061008.
Long Z, Zhang M, Zhang T, Zeng L, Yang K, Yang T, et al. The
Effectiveness and Safety of Mesenchymal Stem Cells in the Treatment of
Osteoarthritis: A Systematic Review and Meta-analysis of 28 Randomized
Controlled Trials. Stem Cells Int. 2022;2022:6151866. doi:
10.1155/2022/6151866.
Zeng W, Wang G, Liao X, Pei C. Efficacy of Intra-Articular Injection of
Platelet-Rich Plasma Combined with Mesenchymal Stem Cells in the
Treatment of Knee Osteoarthritis: A Systematic Review and
Meta-Analysis. Int J Clin Pract. 2022;2022:2192474. doi:
10.1155/2022/2192474.
Ho KK, Lee WY, Griffith JF, Ong MT, Li G. Randomized control trial of
mesenchymal stem cells versus hyaluronic acid in patients with knee
osteoarthritis – A Hong Kong pilot study. J Orthop Translat.
2022;37:69-77. doi: 10.1016/j.jot.2022.07.012.
Tan SHS, Hui JHP. Intra-articular Injections of Mesenchymal Stem Cells
Without Adjuvant Therapies for Knee Osteoarthritis: A Systematic Review
and Meta-analysis: Response. Am J Sports Med.
2022;50(12):NP49-NP50. doi: 10.1177/03635465221112082.
Suh K, Cole BJ, Gomoll A, Lee SM, Choi H, Ha CW, et al. Cost
Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal
Stem Cells in Patients with Knee Osteoarthritis. Appl Health Econ Health
Policy. 2022. doi: 10.1007/s40258-022-00762-9.
Günay AE, Karaman I, Guney A, Karaman ZF, Demirpolat E, Gonen ZB,
et al. Assessment of clinical, biochemical, and radiological outcomes
following intra-articular injection of Wharton jelly-derived mesenchymal
stromal cells in patients with knee osteoarthritis: A prospective clinical
study. Medicine (Baltimore). 2022;101(37):e30628. doi:
10.1097/MD.0000000000030628.
Dhillon J, Kraeutler MJ, Belk JW, Scillia AJ. Umbilical Cord-Derived
Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review.
Orthop J Sports Med. 2022;10(7):23259671221104409. doi:
10.1177/23259671221104409.
Shoukrie SI, Venugopal S, Dhanoa RK, Selvaraj R, Selvamani TY, Zahra
7
A, et al. Safety and Efficacy of Injecting Mesenchymal Stem Cells Into a
Human Knee Joint To Treat Osteoarthritis: A Systematic Review. Cureus.
2022;14(5):e24823. doi: 10.7759/cureus.24823.
Kim KI, Lee WS, Kim JH, Bae JK, Jin W. Safety and Efficacy of the
Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of
Osteoarthritic Knee: A 5-Year Follow-up Study. Stem Cells Transl Med.
2022:szac024. doi: 10.1093/stcltm/szac024.
Gadelkarim M, Elmegeed AA, Hafez A, Awad AK, Shehata MA,
AbouEl-Enein A, et al. Safety and Efficacy of Adipose-Derived
Mesenchymal Stem Cells for Knee Osteoarthritis: A Systematic Review
and Meta-Analysis. Joint Bone Spine. 2022:105404. doi:
10.1016/j.jbspin.2022.105404.
Muthu S, Patil SC, Jeyaraman N, Jeyaraman M, Gangadaran P,
Rajendran RL, et al. Comparative effectiveness of adipose-derived
mesenchymal stromal cells in the management of knee osteoarthritis: A
meta-analysis. World J Orthop. 2023;14(1):23-41. doi:
10.5312/wjo.v14.i1.23.
Di Matteo B, Ranieri R, Manca A, Cappato S, Marcacci M, Kon E,
Castagna A. Cell-Based Therapies for the Treatment of Shoulder and
Elbow Tendinopathies: A Scoping Review. Stem Cells Int.
2021;2021:5558040. doi: 10.1155/2021/5558040.
Ng A, Cavaliere R, Molchan L. Biologics in the Treatment of Plantar
Fasciitis. Clin Podiatr Med Surg. 2021r;38(2):245-259. doi:
10.1016/j.cpm.2020.12.009.
Rodas G, Soler-Rich R, Rius-Tarruella J, Alomar X, Balius R, Orozco L,
et al. Effect of Autologous Expanded Bone Marrow Mesenchymal Stem
Cells or Leukocyte-Poor Platelet-Rich Plasma in Chronic Patellar
Tendinopathy (With Gap >3 mm): Preliminary Outcomes After 6 Months
of a Double-Blind, Randomized, Prospective Study. Am J Sports Med.
2021:363546521998725. doi: 10.1177/0363546521998725.
Cho WS, Chung SG, Kim W, Jo CH, Lee SU, Lee SY. Mesenchymal Stem
Cells Use in the Treatment of Tendon Disorders: A Systematic Review and
Meta-Analysis of Prospective Clinical Studies. Ann Rehabil Med.
2021;45(4):274-283. doi: 10.5535/arm.21078.
Mirghaderi SP, Valizadeh Z, Shadman K, Lafosse T, Oryadi-Zanjani L,
Yekaninejad MS, Nabian MH. Cell therapy efficacy and safety in treating
tendon disorders: a systemic review of clinical studies. J Exp Orthop.
2022;9(1):85. doi: 10.1186/s40634-022-00520-9.
Quintero D, Perucca Orfei C, Kaplan LD, de Girolamo L, Best TM,
Kouroupis D. The roles and therapeutic potentialof mesenchymal
stem/stromal cells and their extracellular vesicles in tendinopathies. Front
Bioeng Biotechnol. 2023;11:1040762. doi:
10.3389/fbioe.2023.1040762.
Wang HN, Rong X, Yang LM, Hua WZ, Ni GX. Advances in Stem Cell
Therapies for Rotator Cuff Injuries. Front Bioeng Biotechnol. 2022. doi:
10.3389/fbioe.2022.866195.
Bono OJ, Jenkin B, Forlizzi J, Mousad A, Le Breton S, MacAskill M, et al.
Evidence for Utilization of Injectable Biologic Augmentation in Primary
Rotator Cuff Repair: A Systematic Review of Data From 2010 to 2022.
Orthop J Sports Med. 2023;11(2):23259671221150037. doi:
10.1177/23259671221150037.
Vadalà G, Ambrosio L, Russo F, Papalia R, Denaro V. Stem Cells and
Intervertebral Disc Regeneration Overview-What They Can and Can’t Do.
Int J Spine Surg. 2021;15(s1):40-53. doi: 10.14444/8054.
Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MÁ,
Sánchez-Lite I, Toribio B, et al. Treatment of Degenerative Disc Disease
With Allogeneic Mesenchymal Stem Cells: Long-term Follow-up Results.
Transplantation. 2021;105(2):e25-e27. doi:
10.1097/TP.0000000000003471.
DI Martino A, Barile F, Fiore M, Ruffilli A, Faldini C. Are injectable
regenerative therapies effective in the treatment of Degenerative Disc
Disease? A systematic literature review. J Neurosurg Sci. 2021. doi:
10.23736/S0390-5616.21.05389-3.
Li B, Yang Y, Wang L, Liu G. Stem Cell Therapy and Exercise for
Treatment of Intervertebral Disc Degeneration. Stem Cells Int.
2021;2021:7982333. doi: 10.1155/2021/7982333.
Haines CM, Bhatt FR, Orosz LD, Yamout T, Namian S, Bharara N, et al.
Low Back Pain, Disability, and Quality of Life One Year following Intradiscal
Injection of Autologous Bone Marrow Aspirate Concentrate. Stem Cells
Int. 2022;2022:9617511. doi: 10.1155/2022/9617511.
Bates D, Vivian D, Freitag J, Wickham J, Mitchell B, Verrills P, et al.
Low-dose mesenchymal stem cell therapy for discogenic pain: safety and
efficacy results from a 1-year feasibility study. Future Sci OA.
2022;8(5):FSO794. doi: 10.2144/fsoa-2021-0155.
Schol J, Sakai D. Comprehensive narrative review on the analysis of
outcomes from cell transplantation clinical trials for discogenic low back
pain. N Am Spine Soc J. 2022;13:100195. doi:
10.1016/j.xnsj.2022.100195.
Sakai D, Schol J, Watanabe M. Clinical Development of Regenerative
Medicine Targeted for Intervertebral Disc Disease. Medicina (Kaunas).
2022;58(2):267. doi: 10.3390/medicina58020267.
Zhang W, Sun T, Li Y, Yang M, Zhao Y, Liu J, Li Z. Application of stem
cells in the repair of intervertebral disc degeneration. Stem Cell Res Ther.
2022;13(1):70. doi: 10.1186/s13287-022-02745-y.
Kaye AD, Edinoff AN, Rosen YE, Boudreaux MA, Kaye AJ, Sheth M, et
al. Regenerative Medicine: Pharmacological Considerations and Clinical
Role in Pain Management. Curr Pain Headache Rep. 2022. doi:
10.1007/s11916-022-01078-y.
Herger N, Bermudez-Lekerika P, Farshad M, Albers CE, Distler O,
Gantenbein B, Dudli S. Should Degenerated Intervertebral Discs of
Patients with Modic Type 1 Changes Be Treated with Mesenchymal Stem
Cells? Int J Mol Sci. 2022;23(5):2721. doi: 10.3390/ijms23052721.
Jia Z, Liu D, Xu J, Wang Q, Zhang L, Yin S, et al. An international analysis
of stem cell research in intervertebral disc degeneration. Stem Cell Res.
2023;67:103044. doi: 10.1016/j.scr.2023.103044.
Wang F, Cheung CW, Wong SSC. Regenerative medicine for the
treatment of chronic low back pain: a narrative review. J Int Med Res.
2023;51(2):3000605231155777. doi: 10.1177/03000605231155777.
Navani A, Manchikanti L, Albers SL, Latchaw RE, Sanapati J, Kaye AD,
et al. Responsible, Safe, and Effective Use of Biologics in the Management
of Low Back Pain: American Society of Interventional Pain Physicians
(ASIPP)Guidelines. Pain Physician. 2019;22(1S):S1-S74.
Padda J, Khalid K, Zubair U, Al Hennawi H, Yadav J, Almanie AH, et al.
Stem Cell Therapy and Its Significance in Pain Management. Cureus.
2021;13(8):e17258. doi: 10.7759/cureus.17258.
Atluri S, Murphy MB, Dragella R, Herrera J, Boachie-Adjei K, Bhati S, et
al. Evaluation of the Effectiveness of Autologous Bone Marrow
Mesenchymal Stem Cells in the Treatment of Chronic Low Back Pain Due
to Severe Lumbar Spinal Degeneration: A 12-Month, Open-Label,
Prospective Controlled Trial. Pain Physician. 2022;25(2):193-207.
Asgharzade S, Talaei A, Farkhondeh T, Forouzanfar F. A review on stem
cell therapy for neuropathic pain. Curr Stem Cell Res Ther. 2020 Feb 13.
doi: 10.2174/1574888X15666200214112908.
Motejunas MW, Bonneval L, Carter C, Reed D, Ehrhardt K. Biologic
Therapy in Chronic Pain Management: a Review of the Clinical Data and
Future Investigations. Curr Pain Headache Rep. 2021;25(5):30. doi:
10.1007/s11916-021-00947-2.
Bryk M, Karnas E, Mlost J, Zuba-Surma E, Starowicz K.
MESENCHYMAL STEM CELLS AND EXTRACELLULAR VESICLES FOR THE
TREATMENT OF PAIN: CURRENT STATUS AND PERSPECTIVES. Br J
Pharmacol. 2021. doi: 10.1111/bph.15569.
Yin Q, Zou T, Sun S, Yang D. Cell therapy for neuropathic pain. Front
Mol Neurosci. 2023;16:1119223. doi: 10.3389/fnmol.2023.1119223.
Yu YQ, Wang H. Imbalance of Th1 and Th2 cytokines and stem cell
therapy in pathological pain. CNS Neurol Disord Drug Targets. 2022. doi:
10.2174/1871527322666221226145828.
Rodriguez-Merchan EC, De la Corte-Rodriguez H. Pain management
in people with hemophilia in childhood and young adulthood. Expert Rev
Hematol. 2021;14(6):525-535. doi: 10.1080/17474086.2021.1935852.
Meroney M, Winegar J, Brown H, Bender M, Smith S, Przkora R.
Modulatory Effects of Stem Cells on Opioid Receptors and
Neuroinflammation. Curr Pain Headache Rep. 2022. doi:
10.1007/s11916-022-01013-1.

CARDIOVASCULAR DISEASES

Sid-Otmane C, Perrault LP, Ly HQ. Mesenchymal stem cell mediates
cardiac repair through autocrine, paracrine and endocrine axes. J Transl
Med. 2020;18(1):336. doi: 10.1186/s12967-020-02504-8.
Vadivel S, Vincent P, Sekaran S, Visaga Ambi S, Muralidar S, Selvaraj V,
et al. Inflammation in myocardial injury- Stem cells as potential
immunomodulators for myocardial regeneration and restoration. Life Sci.
2020;250:117582. doi: 10.1016/j.lfs.2020.117582.
Karimian M, Nouri N, Ghasemi LV, Mohammadi AH, Behjati M.
Administration of stem cells against cardiovascular diseases with a focus
on molecular mechanisms: Current knowledge and prospects. Tissue Cell.
2023;81:102030. doi: 10.1016/j.tice.2023.102030.
Johnson GL, Henry TD, Povsic TJ, Losordo DW, Garberich RF, Stanberry
LI, et al. CD34+ cell therapy significantly reduces adverse cardiac events,
health care expenditures, and mortality in patients with refractory angina.
Stem Cells Transl Med. 2020;9(10):1147-1152. doi:
10.1002/sctm.20-0046.
Konstanty-Kalandyk J, Sadowski J, Kedziora A, Urbanczyk-Zawadzka M,
Baran J, Banys P, et al. Functional Recovery after Intramyocardial Injection
of Adipose-Derived Stromal Cells Assessed by Cardiac Magnetic
Resonance Imaging. Stem Cells Int. 2021;2021:5556800. doi:
10.1155/2021/5556800.
Corban MT, Toya T, Albers D, Sebaali F, Lewis BR, Bois J, et al.
IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for
Treatment of Coronary Endothelial Dysfunction in Patients With Angina
and Nonobstructive Coronary Arteries. Circ Res. 2022;130(3):326-338.
doi: 10.1161/CIRCRESAHA.121.319644.
Shao L, Shen Y, Ren C, Kobayashi S, Asahara T, Yang J. Inflammation in
myocardial infarction: roles of mesenchymal stem cells and their
secretome. Cell Death Discov. 2022;8(1):452. doi:
10.1038/s41420-022-01235-7.
Yu J, Zhang RF, Mao YL, Zhang H. Efficacy and Safety of mesenchymal
stem cell therapy in patients with acute myocardial infarction: a
systematic review and meta-analysis of randomized controlled trials. Curr
Stem Cell Res Ther. 2021. doi: 10.2174/1574888X16666210816111031.
Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A.
Mesenchymal stem cell transplantation after acute myocardial infarction:
a meta-analysis of clinical trials. Stem Cell Res Ther. 2021;12(1):600. doi:
10.1186/s13287-021-02667-1.
Hsiao LC, Lin YN, Shyu WC, Ho M, Lu CR, Chang SS, et al.
First-in-human pilot trial of combined intracoronary and intravenous
mesenchymal stem cell therapy in acute myocardial infarction. Front
Cardiovasc Med. 2022;9:961920. doi: 10.3389/fcvm.2022.961920.
Attar A, Hosseinpour A, Hosseinpour H, Kazemi A. Major
cardiovascular events after bone marrow mononuclear cell
transplantation following acute myocardial infarction: an updated
post-BAMI meta-analysis of randomized controlled trials. BMC
Cardiovasc Disord. 2022;22(1):259. doi: 10.1186/s12872-022-02701-x.
Hosseinpour A, Kheshti F, Kazemi A, Attar A. Comparing the effect of
bone marrow mono-nuclear cells with mesenchymal stem cells after
acute myocardial infarction on improvement of left ventricular function: a
meta-analysis of clinical trials. Stem Cell Res Ther. 2022;13(1):203. doi:
10.1186/s13287-022-02883-3.
Davidson SJ, Roncalli J, Surder D, Corti R, Chugh AR, Yang PC, et al.
Microvascular Obstruction Identifies a Subgroup of Patients Who Benefit
from Stem Cell Therapy Following ST-Elevation Myocardial Infarction. Am
Heart J. 2023:S0002-8703(23)00037-6. doi: 10.1016/j.ahj.2023.02.004.
Gil H, Goldshtein M, Etzion S, Elyagon S, Hadad U, Etzion Y, Cohen S.
Defining the timeline of periostin upregulation in cardiac fibrosis following
acute myocardial infarction in mice. Sci Rep. 2022;12(1):21863. doi:
10.1038/s41598-022-26035-y.
Tripathi A, Khan MS, Khan AR, Vaughn VM, Bolli R. Cell therapy for
nonischemic dilated cardiomyopathy: A systematic review and
meta-analysis of randomized controlled trials. Stem Cells Transl Med.
doi: 10.1002/sctm.21-0094.
Bolli R, Solankhi M, Tang XL, Kahlon A. Cell Therapy in Patients with
Heart Failure: A Comprehensive Review and Emerging Concepts.
Cardiovasc Res. 2021:cvab135. doi: 10.1093/cvr/cvab135.
Kir D, Patel MJ, Munagala MR. What Is the Status of Regenerative
Therapy in Heart Failure? Curr Cardiol Rep. 2021;23(10):146. doi:
10.1007/s11886-021-01575-3.
Domaszk O, Skwarek A, Wojciechowska M. In Search of the Holy Grail:
Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved
Ejection Fraction. Int J Mol Sci. 2023;24(5):4903. doi:
10.3390/ijms24054903.
Bhawnani N, Ethirajulu A, Alkasabera A, Onyali CB, Anim-Koranteng C,
Shah HE, Mostafa JA. Effectiveness of Stem Cell Therapies in Improving
Clinical Outcomes in Patients With Heart Failure. Cureus.
2021;13(8):e17236. doi: 10.7759/cureus.17236.
Diaz-Navarro R, Urrútia G, Cleland JG, Poloni D, Villagran F,
Acosta-Dighero R, et al. Stem cell therapy for dilated cardiomyopathy.
Cochrane Database Syst Rev. 2021;7:CD013433. doi:
10.1002/14651858.CD013433.pub2.
Sim DS, Jones DA, Davies C, Locca D, Veerapen J, Reid A, et al. Cell
administration routes for heart failure: a comparative re-evaluation of the
REGENERATE-DCM and REGENERATE-IHD trials. Regen Med. 2022. doi:
10.2217/rme-2022-0138.
Gyöngyösi M, Pokushalov E, Romanov A, Perin E, Hare JM, Kastrup J,
et al. Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in
Patients with Ischemic Heart Failure by Combination of Individual Patient
Data (IPD) of ACCRUE and Publication-Based Aggregate Data. J Clin Med.
2022;11(11):3205. doi: 10.3390/jcm11113205.
Bolli R, Tang XL. The sad plight of cell therapy for heart failure: causes
and consequences. J Cardiovasc Aging. 2022;2:16. doi:
10.20517/jca.2022.02.
Bolli R, Solankhi M, Tang XL, Kahlon A. Cell therapy in patients with
heart failure: a comprehensive review and emerging concepts. Cardiovasc
Res. 2022;118(4):951-976. doi: 10.1093/cvr/cvab135.
Ogay V, Sekenova A, Li Y, Issabekova A, Saparov A. The Therapeutic
Potential of Mesenchymal Stem Cells in the Treatment of Atherosclerosis.
Curr Stem Cell Res Ther. 2021. doi:
10.2174/1574888X16999210128193549.
Libby P. The changing landscape of atherosclerosis. Nature.
2021;592(7855):524-533. doi: 10.1038/s41586-021-03392-8.
Zhang X, Ren Z, Jiang Z. EndMT-derived mesenchymal stem cells: a
new therapeutic target to atherosclerosis treatment. Mol Cell Biochem.
doi: 10.1007/s11010-022-04544-8.
Egea V, Megens RTA, Santovito D, Wantha S, Brandl R, Siess W, et al.
Properties and fate of human mesenchymal stem cells upon miRNA
let-7f-promoted recruitment to atherosclerotic plaques. Cardiovasc Res.
2022:cvac022. doi: 10.1093/cvr/cvac022.
Sharma S, Pandey NN, Sinha M, Kumar S, Jagia P, Gulati GS, et al.
Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety
and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial
Autologous Bone Marrow-Derived Stem Cells in Patients with Severe
Peripheral Arterial Disease. J Vasc Interv Radiol. 2021;32(2):157-163. doi:
10.1016/j.jvir.2020.09.003.
Gupta PK, Dutta S, Kala S, Nekkanti M, Desai SC, Mahapatra SS, et al.
Phase IV postmarketing surveillance study shows continued efficacy and
safety of Stempeucel in patients with critical limb ischemia due to
Buerger’s disease. Stem Cells Transl Med. 2021;10(12):1602-1613. doi:
10.1002/sctm.21-0197.

PULMONARY DISEASES

van Geffen C, Deißler A, Quante M, Renz H, Hartl D, Kolahian S.
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or
Foes? Front Immunol. 2021;12:663203. doi:
10.3389/fimmu.2021.663203.
Chen Y, Liu X, Tong Z. Mesenchymal Stem Cells in Radiation-Induced
Pulmonary Fibrosis: Future Prospects. Cells. 2022;12(1):6. doi:
10.3390/cells12010006.
Zhang T, Zhang J, Lv C, Li H, Song X. Senescent AECⅡ and the implication
for idiopathic pulmonary fibrosis treatment. Front Pharmacol.
2022;13:1059434. doi: 10.3389/fphar.2022.1059434.
Kletukhina S, Mutallapova G, Titova A, Gomzikova M. Role of
Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic
Pulmonary Fibrosis. Int J Mol Sci. 2022;23(19):11212. doi:
10.3390/ijms231911212.
Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary
fibrosis. Stem Cell Res Ther. 2022;13(1):492. doi:
10.1186/s13287-022-03181-8.
Saleh M, Fotook Kiaei SZ, Kavianpour M. Application of Wharton
jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis.
Stem Cell Res Ther. 2022;13(1):71. doi: 10.1186/s13287-022-02746-x.
Sun QW, Sun Z. Stem cell therapy for pulmonary arterial hypertension:
An update. J Heart Lung Transplant. 2022:S1053-2498(22)01847-2. doi:
10.1016/j.healun.2022.02.020.
Squassoni SD, Sekiya EJ, Fiss E, Lapa MS, Cayetano DDS, Nascimento F,
et al. Autologous Infusion of Bone Marrow and Mesenchymal Stromal
Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I
Randomized Clinical Trial. Int J Chron Obstruct Pulmon Dis.
2021;16:3561-3574. doi: 10.2147/COPD.S332613.
Wang X, Zhao Y, Li D, Feng Y, Xie Y, et al. Intrapulmonary distal airway
stem cell transplantation repairs lung injury in chronic obstructive
pulmonary disease. Cell Prolif. 2021:e13046. doi: 10.1111/cpr.13046.
Cereta AD, Oliveira VR, Costa IP, Afonso JPR, Fonseca AL, de Souza
ART, et al. Emerging Cell-Based Therapies in Chronic Lung Diseases: What
About Asthma? Front Pharmacol. 2021;12:648506. doi:
10.3389/fphar.2021.648506.
Chen YT, Miao K, Zhou L, Xiong WN. Stem cell therapy for chronic
obstructive pulmonary disease. Chin Med J (Engl).
2021;134(13):1535-1545. doi: 10.1097/CM9.0000000000001596.
Armitage JD, Tan DBA, Sturm M, Moodley YP. Transcriptional profiling
of circulating mononuclear cells from patients with chronic obstructive
pulmonary disease receiving mesenchymal stromal cell infusions. Stem
Cells Transl Med. 2021. doi: 10.1002/sctm.21-0024.
Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, Kamrani A,
Valizadeh H, Nadiri M, et al. Chronic obstructive pulmonary disease and
asthma: mesenchymal stem cells and their extracellular vesicles as
potential therapeutic tools. Stem Cell Res Ther. 2022;13(1):262. doi:
10.1186/s13287-022-02938-5.
Calzetta L, Aiello M, Frizzelli A, Camardelli F, Cazzola M, Rogliani P,
Chetta A. Stem Cell-Based Regenerative Therapy and Derived Products in
COPD: A Systematic Review and Meta-Analysis. Cells. 2022;11(11):1797.
doi: 10.3390/cells11111797.

LIVER DISEASES

Ma JF, Gao JP, Shao ZW. Acute liver failure: A systematic review and network
meta-analysis of optimal type of stem cells in animal models. World J Stem Cells.
2023;15(1):1-15. doi: 10.4252/wjsc.v15.i1.1.
Sun H, Shi C, Ye Z, Yao B, Li C, Wang X, Qian Q. The role of mesenchymal stem cells
in liver injury. Cell Biol Int. 2021. doi: 10.1002/cbin.11725.
Shi M, Li YY, Xu RN, Meng FP, Yu SJ, Fu JL, et al. Mesenchymal stem cell therapy
in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized
controlled clinical trial. Hepatol Int. 2021. doi: 10.1007/s12072-021-10199-2.
Schacher FC, Martins Pezzi da Silva A, Silla LMDR, Álvares-da-Silva MR. Bone
Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3:
A Phase I-II Randomized Clinical Trial. Can J Gastroenterol Hepatol.
2021;2021:3662776. doi: 10.1155/2021/3662776.
Zhu CH, Zhang DH, Zhu CW, Xu J, Guo CL, Wu XG, et al. Adult stem cell
transplantation combined with conventional therapy for the treatment of
end-stage liver disease: a systematic review and meta-analysis. Stem Cell Res Ther.
2021;12(1):558. doi: 10.1186/s13287-021-02625-x.
Han J, Lee C, Hur J, Jung Y. Current Therapeutic Options and Potential of
Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease. Cells. 2022;12(1):22.
doi: 10.3390/cells12010022.
Cheng F, Huang Z, Wei W, Li Z. Mesenchymal Stem Cell Transplantation for
hepatitis B virus-related acute-on-chronic liver failure:A systematic review and
meta-analysis. Curr Stem Cell Res Ther. 2022. doi:
10.2174/1574888X18666221214123844.
Gao Y, Yin X, Ren X. Advance of Mesenchymal Stem Cells in Chronic End-Stage
Liver Disease Control. Stem Cells Int. 2022;2022:1526217. doi:
10.1155/2022/1526217.
Li TT, Wang ZR, Yao WQ, Linghu EQ, Wang FS, Shi L. Stem Cell Therapies for
Chronic Liver Diseases: Progress and Challenges. Stem Cells Transl Med.
2022:szac053. doi: 10.1093/stcltm/szac053.
Siapati EK, Roubelakis MG, Vassilopoulos G. Liver Regeneration by
Hematopoietic Stem Cells: Have We Reached the End of the Road? Cells.
2022;11(15):2312. doi: 10.3390/cells11152312.
Yao L, Hu X, Dai K, Yuan M, Liu P, Zhang Q, Jiang Y. Mesenchymal stromal cells:
promising treatment for liver cirrhosis. Stem Cell Res Ther. 2022;13(1):308. doi:
10.1186/s13287-022-03001-z.
Jangra A, Kothari A, Sarma P, Medhi B, Omar BJ, Kaushal K. Recent
Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis. Cells.
2022;11(9):1500. doi: 10.3390/cells11091500.
Nikokiraki C, Psaraki A, Roubelakis MG. The Potential Clinical Use of
Stem/Progenitor Cells and Organoids in Liver Diseases. Cells. 2022;11(9):1410. doi:
10.3390/cells11091410.
Jindal A, Jagdish RK, Kumar A. Hepatic Regeneration in Cirrhosis. J Clin Exp
Hepatol. 2022;12(2):603-616. doi: 10.1016/j.jceh.2021.08.029.
Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve
therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022;13(1):179. doi:
10.1186/s13287-022-02858-4.
Sun X, Guo S. Effectiveness of cell- and colony stimulating factor-based therapy
for liver cirrhosis: a network meta-analysis of randomized controlled trials.
Cytotherapy. 2022:S1465-3249(22)00006-8. doi: 10.1016/j.jcyt.2021.11.006.
Liu Y, Dong Y, Wu X, Xu X, Niu J. The assessment of mesenchymal stem cells
therapy in acute on chronic liver failure and chronic liver disease: a systematic
review and meta-analysis of randomized controlled clinical trials. Stem Cell Res
Ther. 2022;13(1):204. doi: 10.1186/s13287-022-02882-4.
Nandula SR, Nylen ES, Sen S. Novel Therapeutics in Nonalcoholic Fatty Liver
Disease: A Focus on Adult Stem Cells. Metab Syndr Relat Disord. 2023. doi:
10.1089/met.2022.0069.
Yi S, Cong Q, Zhu Y, Xu Q. Mechanisms of Action of Mesenchymal Stem Cells in
Metabolic-Associated Fatty Liver Disease. Stem Cells Int. 2023;2023:3919002. doi:
10.1155/2023/3919002.
Liu P, Qian Y, Liu X, Zhu X, Zhang X, Lv Y, et al. Immunomodulatory role of
mesenchymal stem cell therapy in liver fibrosis. Front Immunol. 2023;13:1096402.
doi: 10.3389/fimmu.2022.1096402.
Zahmatkesh E, Khoshdel Rad N, Hossein-Khannazer N, Mohamadnejad M,
Gramignoli R, Najimi M, et al. Cell and cell-derivative-based therapy for liver
diseases; current approaches and future promises. Expert Rev Gastroenterol
Hepatol. 2023. doi: 10.1080/17474124.2023.2172398.
Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y, Han Z. Mesenchymal stromal cells in
hepatic fibrosis/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol. 2023.
doi: 10.1038/s41423-023-00983-5.
Wang YH, Chen EQ. Mesenchymal Stem Cell Therapy in Acute Liver Failure. Gut
Liver. 2023. doi: 10.5009/gnl220417.
Luo L, Lai C, Feng T, Yao Y, Xue H, Xiang G, Luo L, Huang X. Umbilical cord
blood-derived mesenchymal stem cells transplantation decreases incidence of liver
cancer in end-stage liver disease patients (ESLD): a retrospective analysis over 5
years. Am J Transl Res. 2022;14(8):5848-5858.
Li Z, Zhou X, Han L, Shi M, Xiao H, Lin M, et al. Human Umbilical Cord
Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with
Decompensated Liver Cirrhosis. J Gastrointest Surg. 2023. doi:
10.1007/s11605-022-05528-1.

INFLAMATORY BOWEL DISEASES

Cham B, Witting PK. Editorial Immunomodulatory effects of intestinal
mesenchymal cells in the context of Inflammatory Bowel Disease. Acta
Physiol (Oxf). 2021:e13721. doi: 10.1111/apha.13721.
Huldani H, Margiana R, Ahmad F, Opulencia MJC, Ansari MJ, Bokov DO,
et al. Immunotherapy of inflammatory bowel disease (IBD) through
mesenchymal stem cells. Int Immunopharmacol. 2022;107:108698. doi:
10.1016/j.intimp.2022.108698.
Shi MY, Liu L, Yang FY. Strategies to improve the effect of mesenchymal
stem cell therapy on inflammatory bowel disease. World J Stem Cells.
2022;14(9):684-699. doi: 10.4252/wjsc.v14.i9.684.
Li A, Liu S, Li L, Yu M. Mesenchymal Stem Cells Versus Placebo for
Perianal Fistulizing Crohn’s Disease: A Systemic Review and
Meta-Analysis. Surg Innov. 2023:15533506231157167. doi:
10.1177/15533506231157167.
Fathallah N, Akaffou M, Haouari MA, Spindler L, Alam A, Barré A, et al.
Deep remission improves the quality of life of patients with Crohn’s
disease and anoperineal fistula treated with darvadstrocel: results of a
French pilot study. Tech Coloproctol. 2023. doi:
10.1007/s10151-023-02765-7.
Grim C, Noble R, Uribe G, Khanipov K, Johnson P, Koltun WA, et al.
Impairment of tissue resident mesenchymal stem cells in chronic
ulcerative colitis and Crohn’s disease. J Crohns Colitis. 2021:jjab001. doi:
10.1093/ecco-jcc/jjab001.
Włodarczyk M, Czerwinska K, Włodarczyk J, Fichna J, Dziki A, Dziki Ł.
Current Overview on the Use of Mesenchymal Stem Cells for Perianal
Fistula Treatment in Patients with Crohn’s Disease. Life (Basel).
2021;11(11):1133. doi: 10.3390/life11111133.
Wang R, Yao Q, Chen W, Gao F, Li P, Wu J, et al. Stem cell therapy for
Crohn’s disease: systematic review and meta-analysis of preclinical and
clinical studies. Stem Cell Res Ther. 2021;12(1):463. doi:
10.1186/s13287-021-02533-0.
Sheikholeslami A, Fazaeli H, Khoshandam M, Kalhor N, Eshaghhosseini
SJ, Sheykhhasan M. Use of Mesenchymal Stem Cells in Crohn’s Disease
and Perianal Fistulas: A Narrative Review. Curr Stem Cell Res Ther. 2021.
doi: 10.2174/1574888X16666210916145717.
Che Z, Ye Z, Zhang X, Lin B, Yang W, Liang Y, Zeng J. Mesenchymal
stem/stromal cells in the pathogenesis and regenerative therapy of
inflammatory bowel diseases. Front Immunol. 2022;13:952071. doi:
10.3389/fimmu.2022.952071.
Furukawa S, Mizushima T, Nakaya R, Shibata M, Yamaguchi T,
Watanabe K, Futami K. Darvadstrocel for complex perianal fistulas in
Japanese adults with Crohn’s disease: a phase 3 study. J Crohns Colitis.
2022:jjac144. doi: 10.1093/ecco-jcc/jjac144.
Zhang HM, Yuan S, Meng H, Hou XT, Li J, Xue JC, et al. Stem Cell-Based
Therapies for Inflammatory Bowel Disease. Int J Mol Sci.
2022;23(15):8494. doi: 10.3390/ijms23158494.
Johnson S, Hoch JS, Halabi WJ, Ko J, Nolta J, Dave M. Mesenchymal
Stem/Stromal Cell Therapy Is More Cost-Effective Than Fecal Diversion
for Treatment of Perianal Crohn’s Disease Fistulas. Front Immunol.
2022;13:859954. doi: 10.3389/fimmu.2022.859954.
Wetwittayakhlang P, Al Khoury A, Hahn GD, Lakatos PL. The Optimal
Management of Fistulizing Crohn’s Disease: Evidence beyond
Randomized Clinical Trials. J Clin Med. 2022;11(11):3045. doi:
10.3390/jcm11113045.
Saadh MJ, Mikhailova MV, Rasoolzadegan S, Falaki M, Akhavanfar R,
Gonzáles JLA, et al. Therapeutic potential of mesenchymal stem/stromal
cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD)
therapy. Eur J Med Res. 2023;28(1):47. doi:
10.1186/s40001-023-01008-7.
Reenaers C, Gillard RP, Coimbra C, Gillard RM, Meunier P, Lechanteur
C, et al. Clinical and MRI evolution after local injection of bone
marrow-derived mesenchymal stem cells in perianal fistulae in Crohn’s
disease: results from a prospective monocentric study. J Crohns Colitis.
doi: 10.1093/ecco-jcc/jjac192.
Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal
Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An
Up-to-Date Systematic Review. Biomolecules. 2021;11(1):82. doi:
10.3390/biom11010082.

METABOLIC SYNDROME AND

TYPE 1 AND 2 DIABETES MELLITUS

Ogay V, Sekenova A, Li Y, Issabekova A, Saparov A. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Atherosclerosis. Curr
Stem Cell Res Ther. 2021. doi: 10.2174/1574888X16999210128193549.
Shamsuddin SA, Chan AML, Ng MH, Yazid MD, Law JX, Hj Idrus RB, et al. Stem cells as a potential therapy in managing various disorders of metabolic
syndrome: a systematic review. Am J Transl Res. 2021;13(11):12217-12227.
Wang L, Gao T, Li Y, Xie Y, Zeng S, Tai C, et al. A long-term anti-inflammation markedly alleviated high-fat diet-induced obesity by repeated
administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells. Stem Cell Res Ther. 2022;13(1):259. doi:
10.1186/s13287-022-02935-8.
Cruciani S, Delitala AP, Cossu ML, Ventura C, Maioli M. Management of Obesity and Obesity-Related Disorders: From Stem Cells and Epigenetics to Its
Treatment. Int J Mol Sci. 2023;24(3):2310. doi: 10.3390/ijms24032310.
Paris F, Pizzuti V, Marrazzo P, Pession A, Alviano F, Bonsi L. Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of
Differentiation and Immunomodulation. Int J Mol Sci. 2022;23(23):14597. doi: 10.3390/ijms232314597.
Wang L, Liu T, Liang R, Wang G, Liu Y, Zou J, et al. Mesenchymal stem cells ameliorate β cell dysfunction of human type 2 diabetic islets by reversing β
cell dedifferentiation. EBioMedicine. 2020;51:102615. doi: 10.1016/j.ebiom.2019.102615.
Gao S, Zhang Y, Liang K, Bi R, Du Y. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells Int. 2022;2022:8637493. doi:
10.1155/2022/8637493.
Li Y, Wang F, Liang H, Tang D, Huang M, Zhao J, et al. Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus:
a meta-analysis. Stem Cell Res Ther. 2021;12(1):273. doi: 10.1186/s13287-021-02342-5.
He J, Kong D, Yang Z, Guo R, Amponsah AE, Feng B, Zhang X, Zhang W, Liu A, Ma J, O’Brien T, Cui H. Clinical efficacy on glycemic control and safety of
mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. PLoS One. 2021;16(3):e0247662. doi:
10.1371/journal.pone.0247662.
Mathur A, Taurin S, Alshammary S. The Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes- A Literature Review.
Diabetes Metab Syndr Obes. 2023;16:769-777. doi: 10.2147/DMSO.S392161.
Gomes A, Coelho P, Soares R, Costa R. Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic
approach. Cell Tissue Res. 2021. doi: 10.1007/s00441-021-03461-4.
Lu J, Shen SM, Ling Q, Wang B, Li LR, Zhang W, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1
diabetes: an open parallel controlled clinical study. Stem Cell Res Ther. 2021;12(1):340. doi: 10.1186/s13287-021-02417-3.
Huang Q, Huang Y, Liu J. Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus. Int J Endocrinol.
2021;2021:9938658. doi: 10.1155/2021/9938658.
Pastore I, Assi E, Ben Nasr M, Bolla AM, Maestroni A, Usuelli V, et al. Hematopoietic Stem Cells in Type 1 Diabetes. Front Immunol. 2021;12:694118.
doi: 10.3389/fimmu.2021.694118.
Pires IGS, Silva E Souza JA, de Melo Bisneto AV, Passos XS, Carneiro CC. Clinical efficacy of stem-cell therapy on diabetes mellitus: A systematic review
and meta-analysis. Transpl Immunol. 2022:101740. doi: 10.1016/j.trim.2022.101740.
Jayasinghe M, Prathiraja O, Perera PB, Jena R, Silva MS, Weerawarna PSH, et al The Role of Mesenchymal Stem Cells in the Treatment of Type 1
Diabetes. Cureus. 2022;14(7):e27337. doi: 10.7759/cureus.27337.
Zhang W, Ling Q, Wang B, Wang K, Pang J, Lu J, et al. Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone
marrow in the treatment of type 1 diabetes. Stem Cell Res Ther. 2022;13(1):406. doi: 10.1186/s13287-022-02974-1.
Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani Fet al. Mesenchymal stem cell transplantation in newly diagnosed
type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. Stem Cell Res Ther. 2022;13(1):264. doi:
10.1186/s13287-022-02941-w.
Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2
diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022;13(1):180. doi:
10.1186/s13287-022-02848-6.
Wan XX, Zhang DY, Khan MA, Zheng SY, Hu XM, Zhang Q, et al. Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin
Replacement to Beta-Cell Replacement. Front Endocrinol (Lausanne). 2022;13:859638. doi: 10.3389/fendo.2022.859638.
Wu Z, Xu X, Cai J, Chen J, Huang L, Wu W, et al. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord
mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up. Cytotherapy.
2022:S1465-3249(21)00825-2. doi: 10.1016/j.jcyt.2021.09.015.

CHRONIC RENAL FAILURE

Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion
in diabetic nephropathy: mesangial structure, glomerular biomechanics,
and biochemical signaling and regulation. J Biol Eng. 2022;16(1):19. doi:
10.1186/s13036-022-00299-4.
Lin W, Li HY, Yang Q, Chen G, Lin S, Liao C, Zhou T. Administration of
mesenchymal stem cells in diabetic kidney disease: a systematic review
and meta-analysis. Stem Cell Res Ther. 2021;12(1):43. doi:
10.1186/s13287-020-02108-5.
Wang WJ, Chen XM, Cai GY. Cellular senescence and the
senescence-associated secretory phenotype: Potential therapeutic
targets for renal fibrosis. Exp Gerontol. 2021:111403. doi:
10.1016/j.exger.2021.111403.
Wong CY. Current advances of stem cell-based therapy for kidney
diseases. World J Stem Cells. 2021;13(7):914-933. doi:
10.4252/wjsc.v13.i7.914.
Rangel ÉB, Rodrigues CO, Guimarães-Souza NK. Stem Cell Applications
in Regenerative Medicine for Kidney Diseases. Stem Cells Int.
2021;2021:9817324. doi: 10.1155/2021/9817324.
Ranjbar A, Hassanzadeh H, Jahandoust F, Miri R, Bidkhori HR, Monzavi
SM, et al. Allogeneic adipose-derived mesenchymal stromal cell
transplantation for refractory lupus nephritis: Results of a phase I clinical
trial. Curr Res Transl Med. 2021;70(2):103324. doi:
10.1016/j.retram.2021.103324.
Shao Z, Meng X, Meng F. Efficacy and safety of mesenchymal stem cell
in Chinese patients with chronic renal failure: A pilot study in Shandong
province, China. Pak J Pharm Sci. 2021;34(3(Special)):1227-1231.
Carstens MH, García N, Mandayam S, Workeneh B, Pastora I, Calderón
C, et al. Safety of Stromal Vascular Fraction Cell Therapy for Chronic
Kidney Disease of Unknown Cause (Mesoamerican Nephropathy). Stem
Cells Transl Med. 2022:szac080. doi: 10.1093/stcltm/szac080.
Wang J, Lin Y, Chen X, Liu Y, Zhou T. Mesenchymal stem cells: A new
therapeutic tool for chronic kidney disease. Front Cell Dev Biol.
2022;10:910592. doi: 10.3389/fcell.2022.910592.
Xu N, Liu J, Li X. Therapeutic role of mesenchymal stem cells (MSCs) in
diabetic kidney disease (DKD). Endocr J. 2022. doi:
10.1507/endocrj.EJ22-0123.
Li J, Luo M, Li B, Lou Y, Zhu Y, Bai X, et al. Immunomodulatory Activity
of Mesenchymal Stem Cells in Lupus Nephritis: Advances and
Applications. Front Immunol. 2022;13:843192. doi:
10.3389/fimmu.2022.843192.
Morello W, Budelli S, Bernstein DA, Montemurro T, Montelatici E,
Lavazza C, et al. First clinical application of cord blood mesenchymal
stromal cells in children with multi-drug resistant nephrotic syndrome.
Stem Cell Res Ther. 2022;13(1):420. doi: 10.1186/s13287-022-03112-7.
Hu Q, Chen Y, Deng X, Li Y, Ma X, Zeng J, et al. Diabetic nephropathy:
Focusing on pathological signals, clinical treatment, and dietary
regulation. Biomed Pharmacother. 2023;159:114252. doi:
10.1016/j.biopha.2023.114252.

GRAFT-VERSUS-HOST DISEASE

Colom Díaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic Stem Cell Aging
and Leukemia Transformation. Blood. 2023. doi:
10.1182/blood.2022017933.
Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical
trials assessing mesenchymal stem cell therapy for graft versus host
disease: a systematic review. Stem Cell Res Ther. 2022;13(1):93. doi:
10.1186/s13287-022-02751-0.
Li R, Tu J, Zhao J, Pan H, Fang L, Shi J. Mesenchymal stromal cells as
prophylaxis for graft-versus-host disease in haplo-identical
hematopoietic stem cell transplantation recipients with severe aplastic
anemia?-a systematic review and meta-analysis. Stem Cell Res Ther.
2021;12(1):106. doi: 10.1186/s13287-021-02170-7.
Yu Q, Wang H, Zhang L, Wei W. Advances in the treatment of
graft-versus-host disease with immunomodulatory cells. Int
Immunopharmacol. 2021;92:107349. doi:
10.1016/j.intimp.2020.107349.
Zhang Y, Zheng H, Ren J, Luo X, Zheng Z, Zheng J, et al. Mesenchymal
stem cells enhance the impact of KIR receptor-ligand mismatching on
acute graft-versus-host disease following allogeneic hematopoietic stem
cell transplantation in patients with acute myeloid leukemia but not in
those with acute lymphocytic leukemia. Hematol Oncol. 2021. doi:
10.1002/hon.2867.
Li T, Luo C, Zhang J, Wei L, Sun W, Xie Q, et al. Efficacy and safety of
mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell
transplantation: a systematic review and meta-analysis. Stem Cell Res
Ther. 2021;12(1):246. doi: 10.1186/s13287-021-02304-x.
Bohannon LM, Tang H, Page KM, Ren Y, Jung SH, Artica A, et al.
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood
Transplant vs. Matched Related or Matched Unrelated Donor Transplant
in Patients with Hematologic Malignancies. Transplant Cell Ther.
2021:S2666-6367(21)00893-9. doi: 10.1016/j.jtct.2021.05.002.
Stenger E, Giver CR, Langston A, Kota D, Das PK, Chinnadurai R, et al.
Safety of autologous freshly expanded mesenchymal stromal cells for the
treatment of graft-versus-host disease. Front Immunol.
2022;13:959658. doi: 10.3389/fimmu.2022.959658.
Macías-Sánchez MDM, Morata-Tarifa C, Cuende N, Cardesa-Gil A,
Cuesta-Casas MÁ, Pascual-Cascon MJ, et al. Mesenchymal Stromal Cells
for Treating Steroid-Resistant Acute and Chronic Graft Versus Host
Disease: A Multicenter Compassionate Use Experience. Stem Cells Transl
Med. 2022:szac003. doi: 10.1093/stcltm/szac003.
Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal
stromal cells plus basiliximab, calcineurin inhibitor as treatment of
steroid-resistant acute graft-versus-host disease: a multicenter,
randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.
doi: 10.1186/s13045-022-01240-4.
Shen MZ, Liu XX, Qiu ZY, Xu LP, Zhang XH, Wang Y, et al. Efficacy and
safety of mesenchymal stem cells treatment for multidrug-resistant
graft-versus-host disease after haploidentical allogeneic hematopoietic
stem cell transplantation. Ther Adv Hematol. 2022. doi:
10.1177/20406207211072838.
Doglio M, Crossland RE, Alho AC, Penack O, Dickinson AM, Stary G, et
al. Cell-based therapy in prophylaxis and treatment of chronic
graft-versus-host disease. Front Immunol. 2022;13:1045168. doi:
10.3389/fimmu.2022.1045168.
Ding Y, Liu C, Cai Y, Hou C, Chen G, Xu Y, et al. The efficiency of human
umbilical cord mesenchymal stem cells as a salvage treatment for
steroid-refractory acute graft-versus-host disease. Clin Exp Med. 2023.
doi: 10.1007/s10238-022-00983-1.
Maurer K, Kim HT, Garrity HM, Liney D, Cutler CS, Antin JH, et al. Lower
Incidence of Chronic GVHD Observed after Transplantation with
Cryopreserved Unrelated Allogeneic Stem Cells. Blood Adv. 2023. doi:
10.1182/bloodadvances.2022009231.

AUTOINMUNE AND ALLERGIC DISEASES

Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and Safety of
Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune
Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus,
Inflammatory Bowel Disease, Multiple Sclerosis, and Ankylosing
Spondylitis): A Systematic Review and Meta-Analysis of Randomized
Controlled Trial. Stem Cells Int. 2022;2022:9463314. doi:
10.1155/2022/9463314.
Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A,
Suksatan W, et al. Shining the light on clinical application of mesenchymal
stem cell therapy in autoimmune diseases. Stem Cell Res Ther.
2022;13(1):101. doi: 10.1186/s13287-022-02782-7.
El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent
Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus
Erythematosus; From a Leading Role in Pathogenesis to Potential
Therapeutic Saviors? Front Immunol. 2021;12:643170. doi:
10.3389/fimmu.2021.643170.
Sarsenova M, Issabekova A, Abisheva S, Rutskaya-Moroshan K, Ogay V,
Saparov A. Mesenchymal Stem Cell-Based Therapy for Rheumatoid
Arthritis. Int J Mol Sci. 2021;22(21):11592. doi: 10.3390/ijms222111592.
Muthu S, Jeyaraman M, Ranjan R, Jha SK. Remission is not maintained
over 2 years with hematopoietic stem cell transplantation for rheumatoid
arthritis: A systematic review with meta-analysis. World J Biol Chem.
2021;12(6):114-130. doi: 10.4331/wjbc.v12.i6.114.
Li YJ, Chen Z. Cell-based therapies for rheumatoid arthritis:
opportunities and challenges. Ther Adv Musculoskelet Dis.
2022;14:1759720X221100294. doi: 10.1177/1759720X221100294.
Laranjeira P, Pedrosa M, Duarte C, Pedreiro S, Antunes B, Ribeiro T, et
al. Human Bone Marrow Mesenchymal Stromal/Stem Cells Regulate the
Proinflammatory Response of Monocytes and Myeloid Dendritic Cells
from Patients with Rheumatoid Arthritis. Pharmaceutics. 2022;14(2):404.
doi: 10.3390/pharmaceutics14020404.
Kannan S, Viswanathan P, Gupta PK, Kolkundkar UK. Characteristics of
Pooled Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) and their
Potential Role in Rheumatoid Arthritis Treatment. Stem Cell Rev Rep.
doi: 10.1007/s12015-022-10344-w.
Vij R, Stebbings KA, Kim H, Park H, Chang D. Safety and efficacy of
autologous, adipose-derived mesenchymal stem cells in patients with
rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial.
Stem Cell Res Ther. 2022;13(1):88. doi: 10.1186/s13287-022-02763-w.
Harna B, Kalra P, Arya S, Jeyaraman N, Nallakumarasamy A,
Jeyaraman M, et al. Mesenchymal stromal cell therapy for patients with
rheumatoid arthritis. Exp Cell Res. 2023:113468. doi:
10.1016/j.yexcr.2023.113468.
Ranjbar A, Hassanzadeh H, Jahandoust F, Miri R, Bidkhori HR,
Monzavi SM, et al. Allogeneic adipose-derived mesenchymal stromal cell
transplantation for refractory lupus nephritis: Results of a phase I clinical
20
trial. Curr Res Transl Med. 2021;70(2):103324. doi:
10.1016/j.retram.2021.103324.
Yang C, Sun J, Tian Y, Li H, Zhang L, Yang J, et al. Immunomodulatory
Effect of MSCs and MSCs-Derived Extracellular Vesicles in Systemic
Lupus Erythematosus. Front Immunol. 2021;12:714832. doi:
10.3389/fimmu.2021.714832.
Tang WY, Liu JH, Peng CJ, Liao Y, Luo JS, Sun X, et al. Functional
Characteristics and Application of Mesenchymal Stem Cells in Systemic
Lupus Erythematosus. Arch Immunol Ther Exp (Warsz). 2021;69(1):7. doi:
10.1007/s00005-021-00603-y.
Yang Q, Liu Y, Chen G, Zhang W, Tang S, Zhou T. An Overview of the
Safety, Efficiency, and Signal Pathways of Stem Cell Therapy for Systemic
Lupus Erythematosus. Stem Cells Int. 2021;2021:2168595. doi:
10.1155/2021/2168595.
Li A, Guo F, Pan Q, Chen S, Chen J, Liu HF, Pan Q. Mesenchymal Stem
Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus.
Front Immunol. 2021;12:728190. doi: 10.3389/fimmu.2021.728190.
Yuan X, Sun L. Stem Cell Therapy in Lupus. Rheumatol Immunol Res.
2022;3(2):61-68. doi: 10.2478/rir-2022-0011.
Kamen DL, Wallace C, Li Z, Wyatt M, Paulos C, Wei C, et al. Safety,
immunological effects and clinical response in a phase I trial of umbilical
cord mesenchymal stromal cells in patients with treatment refractory
SLE. Lupus Sci Med. 2022;9(1):e000704. doi:
10.1136/lupus-2022-000704.
Yang L, Ren G, Chen W, Zhao L, Guo J, Ge Y, et al. Long-term follow-up
of autologous peripheral blood hematopoietic stem cell transplantation
for refractory lupus nephritis-a series study of 20 patients. Lupus. 2022.
doi: 10.1177/09612033221126848.
Escobar-Soto CH, Mejia-Romero R, Aguilera N, Alzate-Granados JP,
Mendoza-Pinto C, Munguía-Realpozo P, et al. Human mesenchymal stem
cells for the management of systemic sclerosis. Systematic review.
Autoimmun Rev. 2021. doi: 10.1016/j.autrev.2021.102831.
Velier M, Daumas A, Simoncini S, Arcani R, Magalon J, Benyamine A, et
al. Combining systemic and locally applied cellular therapies for the
treatment of systemic sclerosis. Bone Marrow Transplant. 2021. doi:
10.1038/s41409-021-01492-7.
Farge D, Loisel S, Lansiaux P, Tarte K. Mesenchymal stromal cells for
systemic sclerosis treatment. Autoimmun Rev. 2021:102755. doi:
10.1016/j.autrev.2021.102755.
Hua C, Chen S, Cheng H. Therapeutic potential of mesenchymal stem
cells for refractory inflammatory and immune skin diseases. Hum Vaccin
Immunother. 2022. doi: 10.1080/21645515.2022.2144667.
Khanna D, Krieger N, Sullivan KM. Improving outcomes in
scleroderma: recent progress of cell-based therapies. Rheumatology
(Oxford). 2022. doi: 10.1093/rheumatology/keac628.
Xue E, Minniti A, Alexander T, Del Papa N, Greco R, Cellular-Based
Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell
Transplant to Innovative Approaches. Cells. 2022;11(21):3346. doi:
10.3390/cells11213346.
Zhuang X, Hu X, Zhang S, Li X, Yuan X, Wu Y. Mesenchymal Stem
Cell-Based Therapy as a New Approach for the Treatment of Systemic
Sclerosis. Clin Rev Allergy Immunol. 2022. doi:
10.1007/s12016-021-08892-z.
Cui J, Jin L, Ding M, He J, Yang L, Cui S, et al. Efficacy and safety of
mesenchymal stem cells in the treatment of systemic sclerosis: a
systematic review and meta-analysis. Stem Cell Res Ther. 2022;13(1):118.
doi: 10.1186/s13287-022-02786-3.
Naik PP. Stem cell therapy as a potential treatment option for
psoriasis: a review. An Bras Dermatol. 2022:S0365-0596(22)00077-0.
doi: 10.1016/j.abd.2021.10.002.
Ren X, Zhong W, Li W, Tang M, Zhang K, Zhou F, et al. Human Umbilical
Cord-Derived Mesenchymal Stem Cells Alleviate Psoriasis Through
TNF-α/NF-κB/MMP13 Pathway. Inflammation. 2023. doi:
10.1007/s10753-023-01785-7.
Yao D, Ye S, He Z, Huang Y, Deng J, Wen Z, et al. Adipose-derived
mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results
of a single-arm pilot trial. Ann Transl Med. 2021;9(22):1653. doi:
10.21037/atm-21-5028.
Diotallevi F, Di Vincenzo M, Martina E, Radi G, Lariccia V, Offidani A, et
al. Mesenchymal Stem Cells and Psoriasis: Systematic Review. Int J Mol
Sci. 2022;23(23):15080. doi: 10.3390/ijms232315080.
Hua C, Chen S, Cheng H. Therapeutic potential of mesenchymal stem
cells for refractory inflammatory and immune skin diseases. Hum Vaccin
Immunother. 2022:2144667. doi: 10.1080/21645515.2022.2144667.
Cheng L, Wang S, Peng C, Zou X, Yang C, Mei H, et al. Human umbilical
cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm
study. Signal Transduct Target Ther. 2022;7(1):263. doi:
10.1038/s41392-022-01059-y.
Jiao J, Zhao X, Wang Y, Liang N, Li J, Yang X, et al. Normal mesenchymal
stem cells can improve the abnormal function of T cells in psoriasis via
upregulating transforming growth factor-β receptor. J Dermatol. 2022.
doi: 10.1111/1346-8138.16490.
Shin HT, Lee SH, Yoon HS, Heo JH, Lee SB, Byun JW, et al. Long-term
efficacy and safety of intravenous injection of clonal mesenchymal stem
cells derived from bone marrow in five adults with moderate to severe
atopic dermatitis. J Dermatol. 2021. doi: 10.1111/1346-8138.15928.
Kim EY, Kim HS, Hong KS, Chung HM, Park SP, Noh G. Mesenchymal
stem/stromal cell therapy in atopic dermatitis and chronic urticaria:
immunological and clinical viewpoints. Stem Cell Res Ther.
2021;12(1):539. doi: 10.1186/s13287-021-02583-4.
Legiawati L, Suseno LS, Sitohang IBS, Yusharyahya SN, Ardelia A,
Paramastri K. Stem cells as a therapeutic choice in dermatological
disorders. Curr Stem Cell Res Ther. 2022. doi:
10.2174/1574888X17666220930142513.
Najera J, Hao J. Recent advance in mesenchymal stem cells therapy
for atopic dermatitis. J Cell Biochem. 2022. doi: 10.1002/jcb.30365.

NEURODEGENERATIVE DISEASES

Bonaventura G, Munafò A, Bellanca CM, La Cognata V, Iemmolo R,
Attaguile GA, et al. Stem Cells: Innovative Therapeutic Options for
Neurodegenerative Diseases? Cells. 2021;10(8):1992. doi:
10.3390/cells10081992.
Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal
Stem Cells for Neurological Disorders. Adv Sci (Weinh).
2021;8(7):2002944. doi: 10.1002/advs.202002944.
Zayed MA, Sultan S, Alsaab HO, Yousof SM, Alrefaei GI, Alsubhi NH, et al.
Stem-Cell-Based Therapy: The Celestial Weapon against Neurological
Disorders. Cells. 2022;11(21):3476. doi: 10.3390/cells11213476.
Clark KC, Wang D, Kumar P, Mor S, Kulubya E, Lazar SV, Wang A. The
Molecular Mechanisms Through Which Placental Mesenchymal Stem
Cell-Derived Extracellular Vesicles Promote Myelin Regeneration. Adv Biol
(Weinh). 2022:e2101099. doi: 10.1002/adbi.202101099.
Boffa G, Signori A, Massacesi L, Mariottini A, Sbragia E, Cottone S, et al.
Hematopoietic Stem Cell Transplantation in People With Active
Secondary Progressive Multiple Sclerosis. Neurology. 2022. doi:
10.1212/WNL.0000000000206750.
Zolfaghari Baghbadorani P, Rayati Damavandi A, Moradi S, Ahmadi M,
Bemani P, Aria H, et al. Current advances in stem cell therapy in the
treatment of multiple sclerosis. Rev Neurosci. 2022. doi:
10.1515/revneuro-2022-0102.
Alanazi A, Alassiri M, Jawdat D, Almalik Y. Mesenchymal stem cell
therapy: A review of clinical trials for multiple sclerosis. Regen Ther.
2022;21:201-209. doi: 10.1016/j.reth.2022.07.003.
Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D. Effects of
Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid
Biomarkers in Progressive Multiple Sclerosis. Stem Cells Transl Med.
2022;11(1):55-58. doi: 10.1093/stcltm/szab017.
Baharlooi H, Salehi Z, Minbashi Moeini M, Rezaei N, Azimi M.
Immunomodulatory Potential of Human Mesenchymal Stem Cells and
their Exosomes on Multiple Sclerosis. Adv Pharm Bull.
2022;12(2):389-397. doi: 10.34172/apb.2022.038.
Puyade M, Brunet F, Carolina R, Fergusson N, Makedonov I, Freedman
MS, Atkins H. Autologous Hematopoietic Stem Cell Transplantation for
Multiple Sclerosis, the Ottawa Protocol. Curr Protoc. 2022;2(5):e437. doi:
10.1002/cpz1.437.
Zhang Y, Gu J, Wang X, Li L, Fu L, Wang D, et al. Opportunities and
challenges: mesenchymal stem cells in the treatment of multiple sclerosis.
Int J Neurosci. 2022:1-14. doi: 10.1080/00207454.2022.2042690.
Hendrawan K, Khoo MLM, Visweswaran M, Massey JC, Withers B,
Sutton I, et al. Long-Term Suppression of Circulating Proinflammatory
Cytokines in Multiple Sclerosis Patients Following Autologous
Haematopoietic Stem Cell Transplantation. Front Immunol.
2022;12:782935. doi: 10.3389/fimmu.2021.782935.
Visweswaran M, Hendrawan K, Massey JC, Khoo ML, Ford CD,
23
Zaunders JJ, et al. Sustained immunotolerance in multiple sclerosis after
stem cell transplant. Ann Clin Transl Neurol. 2022. doi:
10.1002/acn3.51510.
De Marchi F, Mareschi K, Ferrero I, Cantello R, Fagioli F, Mazzini L.
Effect of mesenchymal stromal cell transplantation on long-term survival
in amyotrophic lateral sclerosis. Cytotherapy.
2023:S1465-3249(23)00056-7. doi: 10.1016/j.jcyt.2023.02.005.
Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D. A phase II
clinical trial with repeated intrathecal injections of autologous
mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Front Biosci (Landmark Ed). 2021;26(10):693-706. doi: 10.52586/4980.
Cudkowicz ME, Lindborg SR, Goyal NA, Miller RG, Burford MJ, Berry
JD, et al. A Randomized Placebo-Controlled Phase 3 Study of
Mesenchymal stem cells induced to secrete high levels of neurotrophic
factors in Amyotrophic Lateral Sclerosis. Muscle Nerve. 2021. doi:
10.1002/mus.27472.
Nabavi SM, Karimi SH, Arab L, Sanjari L, Mardpour S, Azimian V, et al.
Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal
Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center,
Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up.
Cell J. 2021;23(7):772-778.
Monsour M, Garbuzova-Davis S, Borlongan CV. Patching Up the
Permeability: The Role of Stem Cells in Lessening Neurovascular Damage
in Amyotrophic Lateral Sclerosis. Stem Cells Transl Med. 2022:szac072.
doi: 10.1093/stcltm/szac072.
Lin TJ, Cheng GC, Wu LY, Lai WY, Ling TY, Kuo YC, Huang YH. Potential
of Cellular Therapy for ALS: Current Strategies and Future Prospects.
Front Cell Dev Biol. 2022;10:851613. doi: 10.3389/fcell.2022.851613.
Khalid MU, Masroor T. The promise of stem cells in amyotrophic lateral
sclerosis: a review of clinical trials. J Pak Med Assoc. 2023;73(Suppl
1)(2):S138-S142. doi: 10.47391/JPMA.AKUS-22.
Francesca S, De Marchi F, Mazzini L, Bendotti C. CELL THERAPY IN
ALS: an update on preclinical and clinical studies. Brain Res Bull.
2023:S0361-9230(23)00012-6. doi: 10.1016/j.brainresbull.2023.01.008.
Rodríguez-Pallares J, García-Garrote M, Parga JA, Labandeira-García
JL. Combined cell-based therapy strategies for the treatment of
Parkinson’s disease: focus on mesenchymal stromal cells. Neural Regen
Res. 2023;18(3):478-484. doi: 10.4103/1673-5374.350193.
Shigematsu K, Komori N, Tahara K, Yamagishi H. Repeated infusion of
autologous adipose tissue-derived stem cells for Parkinson’s disease.
Acta Neurol Scand. 2021. doi: 10.1111/ane.13547.
Zeng X, Geng W, Jia J, Wang Z. Advances in Stem Cells Transplantation
for the Therapy of Parkinson’s Disease. Curr Stem Cell Res Ther.
2021;16(8):958-969. doi: 10.2174/1574888X16666210309153949.
Morizane A, Takahashi J. Evading the Immune System: Immune
Modulation and Immune Matching in Cell Replacement Therapies for
Parkinson’s Disease. J Parkinsons Dis. 2021. doi: 10.3233/JPD-212608.
Schiess M, Suescun J, Doursout MF, Adams C, Green C, Saltarrelli JG,
et al. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in
Idiopathic Parkinson’s Disease. Mov Disord. 2021. doi:
10.1002/mds.28582.
Nasrolahi A, Shabani Z, Sadigh-Eteghad S, Salehi-Pourmehr H,
Mahmoudi J. Stem Cell Therapy for the Treatment of Parkinson’s Disease:
What Promise Does it Hold? Curr Stem Cell Res Ther. 2023. doi:
10.2174/1574888X18666230222144116.
Zeng X, Qin H. Stem Cell Transplantation for Parkinson’s Disease:
Current Challenges and Perspectives. Aging Dis. 2022;13(6):1652-1663.
doi: 10.14336/AD.2022.0312.
Lane EL, Lelos MJ. Defining the unknowns for cell therapies in
Parkinson’s disease. Dis Model Mech. 2022;15(10):dmm049543. doi:
10.1242/dmm.049543.
Wang J, Tian Y, Shi X, Feng Z, Jiang L, Hao Y. Safety and Efficacy of Cell
Transplantation on Improving Motor Symptoms in Patients With
Parkinson’s Disease: A Meta-Analysis. Front Hum Neurosci.
2022;16:849069. doi: 10.3389/fnhum.2022.849069.
Nasrolahi A, Shabani Z, Sadigh-Eteghad S, Salehi-Pourmehr H,
Mahmoudi J. Stem Cell Therapy for the Treatment of Parkinson’s Disease:
What Promise Does it Hold? Curr Stem Cell Res Ther. 2023. doi:
10.2174/1574888X18666230222144116.
Borlongan MC, Farooq J, Sadanandan N, Wang ZJ, Cozene B, Lee JY,
Steinberg GK. Stem Cells for Aging-Related Disorders. Stem Cell Rev Rep.
2021;17(6):2054-2058. doi: 10.1007/s12015-021-10222-x.
Hu J, Wang X. Alzheimer’s Disease: From Pathogenesis to
Mesenchymal Stem Cell Therapy – Bridging the Missing Link. Front Cell
Neurosci. 2022;15:811852. doi: 10.3389/fncel.2021.811852.
Ahmad F, Sachdeva P. A consolidated review on stem cell therapy for
treatment and management of Alzheimer’s disease. Aging Med (Milton).
2022;5(3):182-190. doi: 10.1002/agm2.12216.
Regmi S, Liu DD, Shen M, Kevadiya BD, Ganguly A, Primavera R, et al.
Mesenchymal stromal cells for the treatment of Alzheimer’s disease:
Strategies and limitations. Front Mol Neurosci. 2022;15:1011225. doi:
10.3389/fnmol.2022.1011225.
Gonçalves RGJ, Vasques JF, da Silva-Junior AJ, Gubert F,
Mendez-Otero R. Mesenchymal stem cell- and extracellular vesicle-based
therapies for Alzheimer’s disease: progress, advantages, and challenges.
Neural Regen Res. 2023;18(8):1645-1651. doi:
10.4103/1673-5374.361546.
Duan Y, Lyu L, Zhan S. Stem Cell Therapy for Alzheimer’s Disease: A
Scoping Review for 2017-2022. Biomedicines. 2023;11(1):120. doi:
10.3390/biomedicines11010120.
Senthilkumar S, Maiya K, Jain NK, Sundeep M, Mangaonkar S, Prabhu
P, et al. Reversal of Neuropsychiatric Comorbidities in Animal Model of
Temporal Lobe Epilepsy Following Systemic Administration of Dental Pulp
Stem Cells and Bone Marrow Mesenchymal stem cells. Curr Gene Ther.
doi: 10.2174/1566523223666221027113723.
Ramos-Fresnedo A, Perez-Vega C, Domingo RA, Lee SJ, Perkerson
RB, Zubair AC, et al. Mesenchymal stem cell therapy for focal epilepsy: A
systematic review of preclinical models and clinical studies. Epilepsia.
2022;63(7):1607-1618. doi: 10.1111/epi.17266.
Chang BL, Chang KH. Stem Cell Therapy in Treating Epilepsy. Front
Neurosci. 2022;16:934507. doi: 10.3389/fnins.2022.934507.
Szczepanik E, Mierzewska H, Antczak-Marach D, Figiel-Dabrowska A,
Terczynska I, Tryfon J, et al. Intrathecal Infusion of Autologous
Adipose-Derived Regenerative Cells in Autoimmune Refractory Epilepsy:
Evaluation of Safety and Efficacy. Stem Cells Int. 2020. doi:
10.1155/2020/7104243.
Alayli A, Lockard G, Gordon J, Connolly J, Monsour M, Schimmel S, et
al. Stem Cells: Recent Developments Redefining Epilepsy Therapy. Cell
Transplant. 2023:9636897231158967. doi:
10.1177/09636897231158967.
Hlebokazov F, Dakukina T, Potapnev M, Kosmacheva S, Moroz L, Misiuk
N, et al. Clinical benefits of single vs repeated courses of mesenchymal
stem cell therapy in epilepsy patients. Clin Neurol Neurosurg.
2021:106736. doi: 10.1016/j.clineuro.2021.106736.
Aligholi H, Safahani M, Asadi-Pooya AA. Stem cell therapy in patients
with epilepsy: A systematic review. Clin Neurol Neurosurg. 2021. doi:
10.1016/j.clineuro.2020.106416.
Chang BL, Chang KH. Stem Cell Therapy in Treating Epilepsy. Front
Neurosci. 2022;16:934507. doi: 10.3389/fnins.2022.934507.
Shaimardanova AA, Chulpanova DS, Mullagulova AI, Afawi Z,
Gamirova RG, et al. Gene and Cell Therapy for Epilepsy: A Mini Review.
Front Mol Neurosci. 2022;15:868531. doi: 10.3389/fnmol.2022.868531.
Hastuti S, Idroes R, Imran I, Ramli Y, Abas AH, Tallei TE. hUMSC vs.
hUMSC-Exosome: Which One Is Better for Epilepsy? Pharmaceuticals
(Basel). 2022;15(10):1247. doi: 10.3390/ph15101247.
Tesiye MR, Gol M, Fadardi MR, Kani SNM, Costa AM, Ghasemi-Kasman
M, Biagini G. Therapeutic Potential of Mesenchymal Stem Cells in the
Treatment of Epilepsy and Their Interaction with Antiseizure Medications.
Cells. 2022;11(24):4129. doi: 10.3390/cells11244129.
Shaimardanova AA, Chulpanova DS, Mullagulova AI, Afawi Z,
Gamirova RG, Solovyeva VV, Rizvanov AA. Gene and Cell Therapy for
Epilepsy: A Mini Review. Front Mol Neurosci. 2022;15:868531. doi:
10.3389/fnmol.2022.868531.

PERINATAL NEUROLOGICAL DISORDERS

Nabetani M, Mukai T, Shintaku H. Preventing Brain Damage from Hypoxic-Ischemic Encephalopathy in Neonates: Update on Mesenchymal Stromal
Cells and Umbilical Cord Blood Cells. Am J Perinatol. 2021. doi: 10.1055/s-0041-1726451.
Kabatas S, Civelek E, Savrunlu EC, Kaplan N, Boyalı O, Diren F, Can H, Genç A, Akkoç T, Karaöz E. Feasibility of allogeneic mesenchymal stem cells in
pediatric hypoxic-ischemic encephalopathy: Phase I study. World J Stem Cells. 2021;13(5):470-484. doi: 10.4252/wjsc.v13.i5.470.
Kabatas S, Civelek E, Kaplan N, Savrunlu EC, Sezen GB, Chasan M, et al. Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal
stem cells in hypoxic-ischemic encephalopathy. World J Exp Med. 2021;11(2):17-29. doi: 10.5493/wjem.v11.i2.17.
Wellmann S. Stem-cell therapy in neonates – an option? J Perinat Med. 2022. doi: 10.1515/jpm-2022-0507.
Pedroza-García KA, Calderón-Vallejo D, Quintanar JL. Neonatal Hypoxic-Ischemic Encephalopathy: Perspectives of Neuroprotective and
Neuroregenerative Treatments. Neuropediatrics. 2022;53(6):402-417. doi: 10.1055/s-0042-1755235.
Shintaku H. Prevention and treatment of cerebral palsy with cord blood stem cells and cord-derived mesenchymal stem cells. Neural Regen Res.
2021;16(4):672-673. doi: 10.4103/1673-5374.293139.
Sun JM, Case LE, Mikati MA, M Jasien J, McLaughlin C, Waters-Pick B, et al. Sibling umbilical cord blood infusion is safe in young children with cerebral
palsy. Stem Cells Transl Med. 2021. doi: 10.1002/sctm.20-0470.
Amanat M, Majmaa A, Zarrabi M, Nouri M, Akbari MG, Moaiedi AR, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord
tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12(1):439. doi:
10.1186/s13287-021-02513-4.
Shariati M, Esfahani RJ, Bidkhori HR, Sabouri E, Mehrzad S, Sadr-Nabavi A. Cell-based treatment of cerebral palsy: still a long way ahead. Curr Stem
Cell Res Ther. 2021. doi: 10.2174/1574888X16666211102090230.
Qu J, Zhou L, Zhang H, Han D, Luo Y, Chen J, et al. Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis.
Front Bioeng Biotechnol. 2022;10:1006845. doi: 10.3389/fbioe.2022.1006845.
Jensen A. Cerebral palsy – brain repair with stem cells. J Perinat Med. 2022. doi: 10.1515/jpm-2022-0505.
Motavaf M, Dehghan S, Ghajarzadeh M, Ebrahimi N, Zali A, Safari S, Mirmosayyeb O. Stem cell treatment and cerebral palsy: A Systematic review and
meta-analysis. Curr Stem Cell Res Ther. 2022. doi: 10.2174/1574888X18666221201114756.
Cox CS Jr, Juranek J, Kosmach S, Pedroza C, Thakur N, Dempsey A, et al. Autologous cellular therapy for cerebral palsy: a randomized, crossover trial.
Brain Commun. 2022;4(3):fcac131. doi: 10.1093/braincomms/fcac131.
Chand K, Nano R, Wixey J, Patel J. Stem Cell Therapy for Neuroprotection in the Growth-Restricted Newborn. Stem Cells Transl Med.
2022;11(4):372-382. doi: 10.1093/stcltm/szac005.
Maric DM, Radomir M, Milankov Z, Stanojevic I, Vojvodic D, Velikic G, et al. Encouraging effect of autologous bone marrow aspirate concentrate in
rehabilitation of children with cerebral palsy. Eur Rev Med Pharmacol Sci. 2022;26(7):2330-2342. doi: 10.26355/eurrev_202204_28462.
Zarrabi M, Akbari MG, Amanat M, Majmaa A, Moaiedi AR, Montazerlotfelahi H, et al. The safety and efficacy of umbilical cord blood mononuclear cells
in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. BMC Neurol. 2022;22(1):123. doi:
10.1186/s12883-022-02636-y.
Cha B, Kwak H, Bang JI, Jang SJ, Suh MR, Choi JI, et al. Safety and efficacy of allogeneic umbilical cord blood therapy for global development delay
and intellectual disability. Stem Cells Dev. 2023. doi: 10.1089/scd.2022.0252.
Lv Z, Li Y, Wang Y, Cong F, Li X, Cui W, et al. Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a
randomized phase 1/2 controlled trial. Stem Cell Res Ther. 2023;14(1):23. doi: 10.1186/s13287-022-03234-y.

AUTISM SPECTRUM DISORDER (AUTISM)

Kobinia GS, Zaknun JJ, Pabinger C, Laky B. Case Report: Autologous
Bone Marrow Derived Intrathecal Stem Cell Transplant for Autistic
Children – A Report of Four Cases and Literature Review. Front Pediatr.
2021;9:620188. doi: 10.3389/fped.2021.620188.
Simhal AK, Carpenter KLH, Kurtzberg J, Song A, Tannenbaum A, Zhang
L, et aL. Changes in the geometry and robustness of diffusion tensor
imaging networks: Secondary analysis from a randomized controlled trial
of young autistic children receiving an umbilical cord blood infusion. Front
Psychiatry. 2022;13:1026279. doi: 10.3389/fpsyt.2022.1026279.
Shamim S, Khan N, Greene DL, Habiba UE, Umer A. The promise of
autologous and allogeneic cellular therapies in the clinical trials of autism
spectrum disorder. Regen Med. 2023. doi: 10.2217/rme-2022-0176.
Sun JM, Dawson G, Franz L, Howard J, McLaughlin C, Kistler B, et al.
Infusion of human umbilical cord tissue mesenchymal stromal cells in
children with autism spectrum disorder. Stem Cells Transl Med.
2020;9(10):1137–46. doi: 10.1002/sctm.19-0434.
Petriv T, Tatarchuk M, Skuratov A, Rybachuk O, Tsymbaliuk V. Safety of
Combined Autistic Spectrum Disorders Treatment with Umbilical Cord
Mesenchymal Stem Cells Application: Clinical Investigation. Stem Cells
Transl Med. 2021;10(S1):S10. doi: 10.1002/sct3.13017.
Villarreal-Martínez L, González-Martínez G, Sáenz-Flores M,
Bautista-Gómez AJ, González-Martínez A, Ortiz-Castillo M, et al. Stem Cell
Therapy in the Treatment of Patients With Autism Spectrum Disorder: a
Systematic Review and Meta-analysis. Stem Cell Rev Rep. 2021. doi:
10.1007/s12015-021-10257-0.
Villarreal-Martinez L, MartÍnez-Garza LE, Rodriguez-Sanchez IP,
Alvarez-Villalobos N, Guzman-Gallardo F, Pope-Salazar S, et al.
Correlation Between CD133+ Stem Cells and Clinical Improvement in
Patients with Autism Spectrum Disorders Treated with Intrathecal Bone
Marrow-derived Mononuclear Cells. Innov Clin Neurosci.
2022;19(4-6):78-86.
Qu J, Liu Z, Li L, Zou Z, He Z, Zhou L, et al. Efficacy and Safety of Stem
Cell Therapy in Children With Autism Spectrum Disorders: A Systematic
Review and Meta-Analysis. Front Pediatr. 2022;10:897398. doi:
10.3389/fped.2022.897398.

SPINAL CORD INJURIES

Liu S, Zhang H, Wang H, Huang J, Yang Y, Li G, Yu K, Yang L. A Comparative Study of Different Stem Cell Transplantation for Spinal Cord Injury: A Systematic Review and Network Meta-Analysis. World Neurosurg. 2021 Dec 22:S1878-8750(21)01879-9.
Muthu S, Jeyaraman M, Gulati A, Arora A. Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis. Cytotherapy. 2021 Mar;23(3):186-197.
Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156

Khan, S., Mafi, P., Mafi, R., & Khan, W. (2018). A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion. Current stem cell research & therapy, 13(4), 316–323. Available from: https://doi.org/10.2174/1574888X11666170907120030
Liau, L. L., Looi, Q. H., Chia, W. C., Subramaniam, T., Ng, M. H., & Law, J. X. (2020). Treatment of spinal cord injury with mesenchymal stem cells. Cell & bioscience, 10, 112. Available from: https://doi.org/10.1186/s13578-020-00475-3

STROKE

Shen D, Wang H, Zhu H, Jiang C, Xie F, Zhang H, et al. Pre-clinical efficacy
evaluation of human umbilical cord mesenchymal stem cells for ischemic
stroke. Front Immunol. 2023;13:1095469. doi:
10.3389/fimmu.2022.1095469.
Wang K, Rong L, Wei X, Zhang Q, Xiao L. The effectiveness of various
cytotherapeutic strategies for the treatment of ischemic stroke: a
Bayesian network meta-analysis of randomized controlled trials. Neurol
Sci. 2020. doi: 10.1007/s10072-020-04312-w.
Chung JW, Chang WH, Bang OY, Moon GJ, Kim SJ, Kim SK, et al. Efficacy
and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke.
Neurology. 2021:10.1212/WNL.0000000000011440. doi:
10.1212/WNL.0000000000011440.
Chang WH, Lee J, Chung JW, Kim YH, Bang OY, The
Starting-Collaborators. Probable Factors Associated with Response to
Mesenchymal Stem Cell Therapy in Stroke Patients: A Post Hoc Analysis of
the STARTING-2 Trial. J Pers Med. 2021;11(11):1137. doi:
10.3390/jpm11111137.
Lee J, Chang WH, Chung JW, Kim SK, Lee JS, Sohn SI, et al. Efficacy of
Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic
Stroke: A Neuroimaging Study. Stroke. 2021:STROKEAHA121034505.
doi: 10.1161/STROKEAHA.121.034505.
Zhou G, Wang Y, Gao S, Fu X, Cao Y, Peng Y, Zhuang J, Hu J, Shao A,
Wang L. Potential Mechanisms and Perspectives in Ischemic Stroke
Treatment Using Stem Cell Therapies. Front Cell Dev Biol. 2021;9:646927.
doi: 10.3389/fcell.2021.646927.
Abdullahi AM, Abdullahi IM, Sarmast ST, Bhriguvanshi A. Stem Cell
Therapies for Ischemic Stroke: A Systematic Review. Cureus.
2021;13(2):e13139. doi: 10.7759/cureus.13139.
Zhou L, Wang J, Huang J, Song X, Wu Y, Chen X, et al. The role of
mesenchymal stem cell transplantation for ischemic stroke and recent
research developments. Front Neurol. 2022;13:1000777. doi:
10.3389/fneur.2022.1000777.
Tan N, Xin W, Huang M, Mao Y. Mesenchymal stem cell therapy for
ischemic stroke: Novel insight into the crosstalk with immune cells. Front
Neurol. 2022;13:1048113. doi: 10.3389/fneur.2022.1048113.
Wang Z, Wang X, Liao Y, Chen G, Xu K. Immune response treated with
bone marrow mesenchymal stromal cells after stroke. Front Neurol.
2022;13:991379. doi: 10.3389/fneur.2022.991379.
Chen H, Zhou L. Treatment of ischemic stroke with modified
mesenchymal stem cells. Int J Med Sci. 2022;19(7):1155-1162. doi:
10.7150/ijms.74161.
Zhou L, Zhu H, Bai X, Huang J, Chen Y, Wen J, et al. Potential
mechanisms and therapeutic targets of mesenchymal stem cell
transplantation for ischemic stroke. Stem Cell Res Ther. 2022;13(1):195.
doi: 10.1186/s13287-022-02876-2.
Bang OY, Kim EH, Cho YH, Oh MJ, Chung JW, Chang WH, et al.
Circulating Extracellular Vesicles in Stroke Patients Treated With
Mesenchymal Stem Cells: A Biomarker Analysis of a Randomized Trial.
Stroke. 2022:STROKEAHA121036545. doi:
10.1161/STROKEAHA.121.036545.
Ercelen N, Karasu N, Kahyaoglu B, Cerezci O, Akduman RC, Ercelen D,
et al. Clinical experience: Outcomes of mesenchymal stem cell
transplantation in five stroke patients. Front Med (Lausanne).
2023;10:1051831. doi: 10.3389/fmed.2023.1051831.
Kim JT, Youn DH, Kim BJ, Rhim JK, Jeon JP. Recent Stem Cell Research
on Hemorrhagic Stroke: An Update. J Korean Neurosurg Soc. 2022. doi:
10.3340/jkns.2021.0126.
Takamiya S, Kawabori M, Fujimura M. Stem Cell Therapies for
Intracerebral Hemorrhage: Review of Preclinical and Clinical Studies. Cell
Transplant. 2023. doi: 10.1177/09636897231158153.

CENTRAL NERVOUS SYSTEMS (CNS)

TRAUMAS

Mukai T, Sei K, Nagamura-Inoue T. Mesenchymal stromal cells: cell-based therapies for traumatic central nervous system injuries. J Integr Neurosci.
2022;21(2):44. doi: 10.31083/j.jin2102044.
Chen C, Hu N, Wang J, Xu L, Jia XL, Fan X, et al. Umbilical Cord Mesenchymal Stem Cells Promote Neurological Repair After Traumatic Brain Injury
Through Regulating Treg/Th17 Balance. Brain Res. 2021:147711. doi: 10.1016/j.brainres.2021.147711.
Kawabori M, Weintraub AH, Imai H, Zinkevych L, McAllister P, Steinberg GK, et al. Cell Therapy for Chronic TBI: Interim Analysis of the Randomized
Controlled STEMTRA Trial. Neurology. 2021:10. doi: 10.1212/WNL.0000000000011450.
Viet QHN, Nguyen VQ, Le Hoang DM, Thi THP, Tran HP, Thi CHC. Ability to regulate immunity of mesenchymal stem cells in the treatment of traumatic
brain injury. Neurol Sci. 2021. doi: 10.1007/s10072-021-05529-z.
Monsour M, Ebedes D, Borlongan CV. A review of the pathology and treatment of TBI and PTSD. Exp Neurol. 2022:114009. doi:
10.1016/j.expneurol.2022.114009.
Khan A, Bellio MA, Schulman IH, Levi AD, Longsomboon B, Brooks A, et al. The Interdisciplinary Stem Cell Institute’s Use of Food and Drug
Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases. Front Cell Dev Biol.
2021;9:675738. doi: 10.3389/fcell.2021.675738.
Szymoniuk M, Litak J, Sakwa L, Dryla A, Zezulinski W, Czyzewski W, et al. Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for
Spinal Cord Injury. Cells. 2022;12(1):120. doi: 10.3390/cells12010120.
Abdolmohammadi K, Mahmoudi T, Alimohammadi M, Tahmasebi S, Zavvar M, Hashemi SM. Mesenchymal stem cell-based therapy as a new
therapeutic approach for acute inflammatory diseases. Life Sci. 2022:121206. doi: 10.1016/j.lfs.2022.121206.
Ma YH, Liang QY, Ding Y, Han I, Zeng X. Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells. Neurospine. 2022;19(3):616-629. doi:
10.14245/ns.2244272.136.
Brockie S, Fehlings MG. Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells: An Editorial Perspective. Neurospine.
2022;19(3):630-631. doi: 10.14245/ns.2244760.380.
Tahmasebi F, Barati S. Effects of mesenchymal stem cell transplantation on spinal cord injury patients. Cell Tissue Res. 2022. doi:
10.1007/s00441-022-03648-3.
Damianakis EI, Benetos IS, Evangelopoulos DS, Kotroni A, Vlamis J, Pneumaticos SG. Stem Cell Therapy for Spinal Cord Injury: A Review of Recent
Clinical Trials. Cureus. 2022;14(4):e24575. doi: 10.7759/cureus.24575.
Hirota R, Sasaki M, Kataoka-Sasaki Y, Oshigiri T, Kurihara K, Fukushi R, et al. Enhanced network in corticospinal tracts after infused mesenchymal
stem cells in spinal cord injury. J Neurotrauma. 2022 May 25. doi: 10.1089/neu.2022.0106.
Zipser CM, Cragg JJ, Guest JD, Fehlings MG, Jutzeler CR, Anderson AJ, Curt A. Cell-based and stem-cell-based treatments for spinal cord injury:
evidence from clinical trials. Lancet Neurol. 2022:S1474-4422(21)00464-6. doi: 10.1016/S1474-4422(21)00464-6.
Xu X, Liang Z, Lin Y, Rao J, Lin F, Yang Z, et al. Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review
and Bayesian Network Meta-Analysis. Front Cell Neurosci. 2022;16:860131. doi: 10.3389/fncel.2022.860131.
Saini R, Pahwa B, Agrawal D, Singh PK, Gujjar H, Mishra S, et al. Efficacy and outcome of bone marrow derived stem cells transplanted via
intramedullary route in acute complete spinal cord injury – A randomized placebo controlled trial. J Clin Neurosci. 2022;100:7-14. doi:
10.1016/j.jocn.2022.03.033.
de Araújo LT, Macêdo CT, Damasceno PKF, das Neves ÍGC, de Lima CS, Santos GC, et al. Clinical Trials Using Mesenchymal Stem Cells for Spinal Cord
Injury: Challenges in Generating Evidence. Cells. 2022;11(6):1019. doi: 10.3390/cells11061019.
Ribeiro B, Cruz B, de Sousa BM, Correia PD, David N, Rocha C, et al. Cell therapies for spinal cord injury: a review of the clinical trials and cell-type
therapeutic potential. Brain. 2023. doi: 10.1093/brain/awad047.

FEMALE INFERTILITY

Shareghi-Oskoue O, Aghebati-Maleki L, Yousefi M. Transplantation of
human umbilical cord mesenchymal stem cells to treat premature ovarian
failure. Stem Cell Res Ther. 2021;12(1):454. doi:
10.1186/s13287-021-02529-w.
Ali I, Padhiar AA, Wang T, He L, Chen M, Wu S, et al. Stem Cell-Based
Therapeutic Strategies for Premature Ovarian Insufficiency and Infertility:
A Focus on Aging. Cells. 2022;11(23):3713. doi: 10.3390/cells11233713.
Niu J, Yu F, Luo X, Chen S. Human Umbilical Cord Mesenchymal Stem
Cells Improve Premature Ovarian Failure through Cell Apoptosis of
miR-100-5p/NOX4/NLRP3. Biomed Res Int. 2022;2022:3862122. doi:
10.1155/2022/3862122.
Naeem A, Gupta N, Naeem U, Elrayess MA, Albanese C. Amniotic stem
cells as a source of regenerative medicine to treat female infertility. Hum
Cell. 2022. doi: 10.1007/s13577-022-00795-1.
Rosario R, Anderson RA. Novel approaches to fertility restoration in
women with premature ovarian insufficiency. Climacteric. 2021:1-13. doi:
10.1080/13697137.2020.1856806.
Tinjic S, Abazovic D, Ljubic D, Vojvodic D, Božanovic T, Ibrišimovic M, et
al. Influence of Autologous In Vitro Activation of Ovaries by Stem Cells and
Growth Factors on Endocrine and Reproductive Function of Patients with
Ovarian Insufficiency-A Clinical Trial Study. Int J Fertil Steril.
2021;15(3):178-188. doi: 10.22074/IJFS.2020.134678.
Saeed Y, Liu X. Mesenchymal stem cells to treat female infertility; future
perspective and challenges: A review. Int J Reprod Biomed.
2022;20(9):709-722. doi: 10.18502/ijrm.v20i9.12061.
Rezayat F, Esmaeil N, Rezaei A. Potential Therapeutic Effects of Human
Amniotic Epithelial Cells on Gynecological Disorders Leading to Infertility
or Abortion. Stem Cell Rev Rep. 2022. doi:
10.1007/s12015-022-10464-3.
Wu JX, Xia T, She LP, Lin S, Luo XM. Stem Cell Therapies for Human
Infertility: Advantages and Challenges. Cell Transplant. 2022. doi:
10.1177/09636897221083252.
Ghajari G, Heydari A, Ghorbani M. Mesenchymal stem cell-based
therapy and female infertility: limitations and advances. Curr Stem Cell
Res Ther. 2022. doi: 10.2174/1574888X17666220511142930.
Pellicer N, Cozzolino M, Diaz-García C, Galliano D, Cobo A, Pellicer A, et
al. Ovarian rescue in women with premature ovarian insufficiency: facts
and fiction. Reprod Biomed Online. 2022:S1472-6483(22)00861-6. doi:
10.1016/j.rbmo.2022.12.011.
Gao H, Gao L, Wang W. Advances in the cellular immunological
pathogenesis and related treatment of primary ovarian insufficiency. Am
J Reprod Immunol. 2022. doi: 10.1111/aji.13622.
Mohamed Rasheed ZB, Nordin F, Wan Kamarul Zaman WS, Tan YF,
Abd Aziz NH. Autologous Human Mesenchymal Stem Cell-Based Therapy
in Infertility: New Strategies and Future Perspectives. Biology (Basel).
2023;12(1):108. doi: 10.3390/biology12010108.
Umer A, Khan N, Greene DL, Habiba UE, Shamim S, Khayam AU. The
Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal
Stem Cells for the Treatment of Premature Ovarian Failure. Stem Cell Rev
Rep. 2022. doi: 10.1007/s12015-022-10493-y.
Huang Y, Zhu M, Liu Z, Hu R, Li F, Song Y, Geng Y, Ma W, Song K, Zhang
M. Bone marrow mesenchymal stem cells in premature ovarian failure:
Mechanisms and prospects. Front Immunol. 2022;13:997808. doi:
10.3389/fimmu.2022.997808.
Garg K, Zilate S. Umbilical Cord-Derived Mesenchymal Stem Cells for
the Treatment of Infertility Due to Premature Ovarian Failure. Cureus.
2022;14(10):e30529. doi: 10.7759/cureus.30529.

AGING AND FRAILTY

Johnson AA, English BW, Shokhirev MN, Sinclair DA, Cuellar TL. Human age reversal: Fact or fiction? Aging Cell. 2022:e13664. doi: 10.1111/acel.13664.
Murtagh FEM, Okoeki M, Ukoha-Kalu BO, Khamis A, Clark J, Boland JW, et al. A non-randomised controlled study to assess the effectiveness of a new
proactive multidisciplinary care intervention for older people living with frailty. BMC Geriatr. 2023;23(1):6. doi: 10.1186/s12877-023-03727-2.
Rasouli M, Naeimzadeh Y, Hashemi N, Hosseinzadeh S. Age-Related Alterations in Mesenchymal Stem Cell Function: Understanding Mechanisms and
Seeking Opportunities to Bypass the Cellular Aging. Curr Stem Cell Res Ther. 2023. doi: 10.2174/1574888X18666230113144016.
Yeo GEC, Ng MH, Nordin FB, Law JX. Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System. Int J Mol Sci.
2021;22(11):5749. doi: 10.3390/ijms22115749.
Zhang L, Liu Q, Hu H, Zhao L, Zhu K. Progress in mesenchymal stem cell mitochondria transfer for the repair of tissue injury and treatment of disease.
Biomed Pharmacother. 2022 doi: 10.1016/j.biopha.2022.113482.
Fraile M, Eiro N, Costa LA, Martín A, Vizoso FJ. Aging and Mesenchymal Stem Cells: Basic Concepts, Challenges and Strategies. Biology (Basel). 2022.
doi: 10.3390/biology11111678.
Pignolo RJ. Aging and Bone Metabolism. Compr Physiol. 2023;13(1):4355-4386. doi: 10.1002/cphy.c220012.
Branco A, Moniz I, Ramalho-Santos J. Mitochondria as biological targets for stem cell and organismal senescence. Eur J Cell Biol. 2023;102(2):151289.
doi: 10.1016/j.ejcb.2023.151289.
Guderyon MJ, Chen C, Bhattacharjee A, Ge G, Fernandez RA, Gelfond JAL, et al. Mobilization-based transplantation of young-donor hematopoietic
stem cells extends lifespan in mice. Aging Cell. 2020. doi: 10.1111/acel.13110.
Wang B, Liu Z, Chen VP, Wang L, Inman CL, Zhou Y, et al. Transplanting cells from old but not young donors causes physical dysfunction in older
recipients. Aging Cell. 2020. doi: 10.1111/acel.13106.
Lv M, Zhang S, Jiang B, Cao S, Dong Y, Cao L, Guo S. Adipose-derived stem cells regulate metabolic homeostasis and delay aging by promoting
mitophagy. FASEB J. 2021. doi: 10.1096/fj.202100332R.
Yu Q, Tian C, Lv G, Kong Q, Li G, Zhu G, et al. Bone marrow mesenchymal stem cells derived from juvenile macaques reversed serum protein
expression profile in aged macaques. Curr Stem Cell Res Ther. 2022. doi: 10.2174/1574888X17666220429111218.
Zamorano M, Alexander JF, Catania D, Dharmaraj S, Kavelaars A, Heijnen CJ. Nasal administration of mesenchymal stem cells prevents accelerated
age-related tauopathy after chemotherapy in mice. Immun Ageing. 2023. doi: 10.1186/s12979-023-00328-w.
Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, et al. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
J Gerontol A Biol Sci Med Sci. 2017. doi: 10.1093/gerona/glx056.
Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, et al. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II
Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2017. doi: 10.1093/gerona/glx137.
Schulman IH, Balkan W, Hare JM. Mesenchymal Stem Cell Therapy for Aging Frailty. Front Nutr. 2018;5:108. doi: 10.3389/fnut.2018.00108.
Sun X, Hao Q, Tang R, Xiao C, Ge M, Dong B. Frailty and Rejuvenation with Stem Cells: Therapeutic Opportunities and Clinical Challenges. Rejuvenation
Res. 2019. doi: 10.1089/rej.2017.2048.
Oliva AA, McClain-Moss L, Pena A, Drouillard A, Hare JM. Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to
geroscience. Aging Med (Milton). 2019;2(3):142-146. doi: 10.1002/agm2.12079.
Florea V, Bagno L, Rieger AC, Hare J. Attenuation of frailty in older adults with mesenchymal stem cells. Mech Ageing Dev. 2019.
doi:10.1016/j.mad.2019.111120.
Hoang DM, Nguyen KT, Hoang VT, Dao LTM, Bui HT, Ho TTK, et al. Clinical study of mesenchymal stem/stromal cell therapy for the treatment of frailty:
a proposed experimental design for therapeutic and mechanistic investigation. J Gerontol A Biol Sci Med Sci. 2021. doi: 10.1093/gerona/glab326.
Zhu Y, Ge J, Huang C, Liu H, Jiang H. Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics. Theranostics.
2021;11(12):5675-5685. doi: 10.7150/thno.46436.
Borlongan MC, Farooq J, Sadanandan N, Wang ZJ, Cozene B, Lee JY, et al. Stem Cells for Aging-Related Disorders. Stem Cell Rev Rep.
2021;17(6):2054-2058. doi: 10.1007/s12015-021-10222-x.
Lv X, Niu H. Mesenchymal Stem Cell Transplantation for the Treatment of Cognitive Frailty. J Nutr Health Aging. 2021;25(6):795-801. doi:
10.1007/s12603-021-1632-4.
Hare JM, Beerman I. Stem cells’ potential to restore function in aging systems; are we there yet? J Gerontol A Biol Sci Med Sci. 2022:glac003. doi:
10.1093/gerona/glac003.
Fraile M, Eiro N, Costa LA, Martín A, Vizoso FJ. Aging and Mesenchymal Stem Cells: Basic Concepts, Challenges and Strategies. Biology (Basel).
2022;11(11):1678. doi: 10.3390/biology11111678.

SKIN DISORDERS AND ALOPECIA.

AESTHETIC MEDICINE

Li Y, Ye Z, Yang W, Zhang Q, Zeng J. An Update on the Potential of
Mesenchymal Stem Cell Therapy for Cutaneous Diseases. Stem Cells Int.
2021;2021:8834590. doi: 10.1155/2021/8834590.
Bojanic C, To K, Hatoum A, Shea J, Seah KTM, Khan W, Malata CM.
Mesenchymal stem cell therapy in hypertrophic and keloid scars. Cell
Tissue Res. 2021 Jan 2. doi: 10.1007/s00441-020-03361-z.
Chen H, Hou K, Wu Y, Liu Z. Use of Adipose Stem Cells Against
Hypertrophic Scarring or Keloid. Front Cell Dev Biol. 2022;9:823694. doi:
10.3389/fcell.2021.823694.
Arango-Rodríguez ML, Solarte-David VA, Becerra-Bayona SM,
Callegari E, Paez MD, Sossa CL, et al. Role of mesenchymal stromal cells
derivatives in diabetic foot ulcers: a controlled randomized phase 1/2
clinical trial. Cytotherapy. 2022;24(10):1035-1048. doi:
10.1016/j.jcyt.2022.04.002.
Sharma P, Kumar A, Dey AD. Cellular Therapeutics for Chronic Wound
healing: Future for Regenerative Medicine. Curr Drug Targets. 2022. doi:
10.2174/138945012309220623144620.
Nalisa DL, Moneruzzaman M, Changwe GJ, Mobet Y, Li LP, Ma YJ, Jiang
HW. Stem Cell Therapy for Diabetic Foot Ulcers: Theory and Practice. J
Diabetes Res. 2022;2022:6028743. doi: 10.1155/2022/6028743.
Sun Y, Zhao J, Zhang L, Li Z, Lei S. Effectiveness and safety of stem cell
therapy for diabetic foot: a meta-analysis update. Stem Cell Res Ther.
2022;13(1):416. doi: 10.1186/s13287-022-03110-9.
Mastrogiacomo M, Nardini M, Collina MC, Di Campli C, Filaci G,
Cancedda R, Odorisio T. Innovative Cell and Platelet Rich Plasma
Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach.
Front Bioeng Biotechnol. 2022;10:869408. doi:
10.3389/fbioe.2022.869408.
Kerstan A, Dieter K, Niebergall-Roth E, Dachtler AK, Kraft K, Stücker M,
et al. Allogeneic ABCB5+ mesenchymal stem cells for
treatment-refractory chronic venous ulcers: a phase I/IIa clinical trial. JID
Innov. 2022;2(1):100067. doi: 10.1016/j.xjidi.2021.100067.
Falanga V, Grada A, Otero-Vinas M, Lin X, Yufit T, Fiore D, Carson P.
Autologous Cultured Bone Marrow-Derived Mesenchymal Stem Cells in a
Fibrin Spray to Treat Venous Ulcers: A Randomized Controlled
Double-Blind Pilot Study. Surg Technol Int. 2022;40:sti40/1493.
Verdi J, Shirian S, Saleh M, Khadem Haghighian H, Kavianpour M.
Mesenchymal Stem Cells Regenerate Diabetic Foot Ulcers: A Review
Article. World J Plast Surg. 2022;11(1):12-22. doi:
10.52547/wjps.11.1.12.
Elsharkawi M, Ghoneim B, Westby D, Jones D, Tawfick W, Walsh SR.
Adipose-derived stem cells in patients with venous ulcers: Systematic
review. Vascular. 2022:17085381221098279. doi:
10.1177/17085381221098279.
Zhang C, Huang L, Wang X, Zhou X, Zhang X, Li L, et al. Topical and
intravenous administration of human umbilical cord mesenchymal stem
cells in patients with diabetic foot ulcer and peripheral arterial disease: a
phase I pilot study with a 3-year follow-up. Stem Cell Res Ther.
2022;13(1):451. doi: 10.1186/s13287-022-03143-0.
Mrozikiewicz-Rakowska B, Szabłowska-Gadomska I, Cysewski D,
Rudzinski S, Płoski R, Gasperowicz P, et al. Allogenic Adipose-Derived
Stem Cells in Diabetic Foot Ulcer Treatment: Clinical Effectiveness, Safety,
Survival in the Wound Site, and Proteomic Impact. Int J Mol Sci.
2023;24(2):1472. doi: 10.3390/ijms24021472.
Huerta CT, Voza FA, Ortiz YY, Liu ZJ, Velazquez OC. Mesenchymal stem
cell-based therapy for non-healing wounds due to chronic
limb-threatening ischemia: A review of preclinical and clinical studies.
Front Cardiovasc Med. 2023. doi: 10.3389/fcvm.2023.1113982.
Tak YJ, Lee SY, Cho AR, Kim YS. A randomized, double-blind,
vehicle-controlled clinical study of hair regeneration using
adipose-derived stem cell constituent extract in androgenetic alopecia.
Stem Cells Transl Med. 2020. doi: 10.1002/sctm.19-0410.
Mysore V, Alexander S, Nepal S, Venkataram A. Regenerative Medicine
Treatments for Androgenetic Alopecia. Indian J Plast Surg.
2021;54(4):514-520. doi: 10.1055/s-0041-1739257.
Gentile P, Alves R, Cole JP, Andjelkov K, Van Helmelryck T, Fernandez J,
et al. AIRMESS – Academy of International Regenerative Medicine &
Surgery Societies: Recommendations in the use of Platelet-Rich Plasma
(PRP), Autologous Stem Cell-Based Therapy (ASC-BT) in Androgenetic
Alopecia and Wound Healing. Expert Opin Biol Ther. 2021. doi:
10.1080/14712598.2021.1908995.
Kim SJ, Kim MJ, Lee YJ, Lee JC, Kim JH, Kim DH, et al. Innovative
method of alopecia treatment by autologous adipose-derived SVF. Stem
Cell Res Ther. 2021;12(1):486. doi: 10.1186/s13287-021-02557-6.
El-Khalawany M, Rageh MA, Elnokrashy I, Ibrahim SMA. Efficacy of
autologous stromal vascular fraction injection in the treatment of
androgenic alopecia. Arch Dermatol Res. 2022. doi:
10.1007/s00403-022-02501-5.
Montero-Vilchez T, Sierra-Sánchez Á, Sanchez-Diaz M, Quiñones-Vico
MI, Sanabria-de-la-Torre R, Martinez-Lopez A, Arias-Santiago S.
Mesenchymal Stromal Cell-Conditioned Medium for Skin Diseases: A
Systematic Review. Front Cell Dev Biol. 2021;9:654210. doi:
10.3389/fcell.2021.654210.
Putri KT, Prasetyono TOH. A critical review on the potential role of
adipose-derived stem cells for future treatment of hypertrophic scars. J
Cosmet Dermatol. 2021. doi: 10.1111/jocd.14385.
Jo H, Brito S, Kwak BM, Park S, Lee MG, Bin BH. Applications of
Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation. Int J Mol
Sci. 2021;22(5):2410. doi: 10.3390/ijms22052410.
Chang WL, Lee WR, Kuo YC, Huang YH. Vitiligo: An Autoimmune Skin
Disease and its Immunomodulatory Therapeutic Intervention. Front Cell
Dev Biol. 2021;9:797026. doi: 10.3389/fcell.2021.797026.
Crowley JS, Liu A, Dobke M. Regenerative and stem cell-based
techniques for facial rejuvenation. Exp Biol Med (Maywood).
2021:15353702211020701. doi: 10.1177/15353702211020701.
Zhang M, Xia T, Lin F, Yu J, Yang Y, Lei W, Zhang T. Vitiligo: An immune
disease and its emerging mesenchymal stem cell therapy paradigm.
Transpl Immunol. 2022:101766. doi: 10.1016/j.trim.2022.101766.
Liang X, Li J, Yan Y, Xu Y, Wang X, Wu H, et al. Efficacy of Microneedling
Combined With Local Application of Human Umbilical Cord-Derived
Mesenchymal Stem Cells Conditioned Media in Skin Brightness and
Rejuvenation: A Randomized Controlled Split-Face Study. Front Med
(Lausanne). 2022;9:837332. doi: 10.3389/fmed.2022.837332.
Lin TJ, Huang YL, Kang YN, Chen C. Effectiveness of Topical
Conditioned Medium of Stem Cells in Facial Skin Nonsurgical Resurfacing
Modalities for Antiaging: Systematic Review and Meta-Analysis of
Randomized Controlled Trials. Aesthetic Plast Surg. 2022. doi:
10.1007/s00266-022-03168-z.
Roohaninasab M, Seifadini A, Atefi N, Sadeghzadeh-Bazargan A,
Goodarzi A, Hanifnia AR, et al. Evaluating the effectiveness of
Stromal-Vascular Fraction (SVF) cells along with subcision method in the
treatment of acne scars: a double blind randomized controlled clinical trial
study. J Cosmet Dermatol. 2022. doi: 10.1111/jocd.15375.
Svolacchia L, Prisco C, Giuzio F, Svolacchia F. Adipose Autologous
Micrograft and Its Derived Mesenchymal Stem Cells in a Bio Cross-Linked
Hyaluronic Acid Scaffold for Correction Deep Wrinkles, Facial Depressions,
Scars, Face Dermis and Its Regenerations: A Pilot Study and Cases
Report. Medicina (Kaunas). 2022;58(11):1692. doi:
10.3390/medicina58111692.
Qian H, Shan Y, Gong R, Lin D, Zhang M, Wang C, et al. Mechanism of
action and therapeutic effects of oxidative stress and stem cell-based
materials in skin aging: Current evidence and future perspectives. Front
Bioeng Biotechnol. 2023;10:1082403. doi:
10.3389/fbioe.2022.1082403.

EXTRA CELLULAR VESICLES (VEs)

Karnas E, Dudek P, Zuba-Surma EK. Stem cell- derived extracellular
vesicles as new tools in regenerative medicine – Immunomodulatory role
and future perspectives. Front Immunol. 2023;14:1120175. doi:
10.3389/fimmu.2023.1120175.
Ridzuan N, Widera D, Yahaya BH. Isolation and Characterization of
Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal
Stem Cells. Methods Mol Biol. 2022;2429:271-280. doi:
10.1007/978-1-0716-1979-7_18.
Turano E, Scambi I, Virla F, Bonetti B, Mariotti R. Extracellular Vesicles
from Mesenchymal Stem Cells: Towards Novel Therapeutic Strategies for
Neurodegenerative Diseases. Int J Mol Sci. 2023;24(3):2917. doi:
10.3390/ijms24032917.
Karimian A, Khoshnazar SM, Kazemi T, Asadi A, Abdolmaleki A. Role of
secretomes in cell-free therapeutic strategies in regenerative medicine.
Cell Tissue Bank. 2023. doi: 10.1007/s10561-023-10073-5.
Ranjan P, Colin K, Dutta RK, Verma SK. Challenges and future scope of
exosomes in the treatment of cardiovascular diseases. J Physiol. 2022.
doi: 10.1113/JP282053.
Cai H, Guo H. Mesenchymal Stem Cells and Their Exocytotic Vesicles. Int
J Mol Sci. 2023;24(3):2085. doi: 10.3390/ijms24032085.
Okamura A, Yoshioka Y, Saito Y, Ochiya T. Can Extracellular Vesicles as
Drug Delivery Systems Be a Game Changer in Cardiac Disease? Pharm
Res. 2022. doi: 10.1007/s11095-022-03463-z.
Joo HS, Jeon HY, Hong EB, Kim HY, Lee JM. Exosomes for the diagnosis
and treatment of dementia. Curr Opin Psychiatry. 2023;36(2):119-125.
doi: 10.1097/YCO.0000000000000842.
Claridge B, Lozano J, Poh QH, Greening DW. Development of
Extracellular Vesicle Therapeutics: Challenges, Considerations, and
Opportunities. Front Cell Dev Biol. 2021;9:734720. doi:
10.3389/fcell.2021.734720.
Li L, Wu P, Qian H, Xu W, Shi H, Jiang J. Tailored Extracellular Vesicles:
Novel Tool for Tissue Regeneration. Stem Cells Int. 2022. doi:
10.1155/2022/7695078.
A review on exosomes application in clinical trials: perspective,
questions, and challenges. Cell Commun Signal. 2022;20(1):145. doi:
10.1186/s12964-022-00959-4.